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Aim of the Thesis 
It was the main goal to understand the cellular and molecular underpinnings relevant for tumor 
protection and rejection. Whilst the potency of IL-12 as a tumor-suppressing cytokine has been clearly 
established, the fact that systemic application led to severe adverse effects has halted the 
development of IL-12 threapies in humans. However, to this day, the molecular and cellular events are 
ill-understood. By defining the mechanistic underpinnings, we wanted to shed light onto how tumor 
cells and immune cells interact in general and in particular will enhance the therapeutic targeting of 
malignancies in humans. 
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Summary 
 
Lymphocytes and their secreted cytokines play a critical role in tumor control and elimination. In a 
variety of tumor models, Interleukin-12 has been shown to repress tumor growth. The tumoricidal 
activity of IL-12 is widely held to be mediated by the activation and polarization of NK and type 1 T 
helper cells respectively. The purpose of this project was to specifically determine the precise 
mechanism by which IL-12 mediates tumor suppression rather than investigating its potential clinical 
application. By systematic analysis of the immune response to an Interleukin-12 secreting melanoma 
cell line (B16-F10) we found that tumor suppression is mediated independently of T lymphocytes or 
NK cells. We discovered that IL-12 initiates powerful local anti-tumor immunity by stimulating a subset 
of lymphoid tissue inducer cells dependent on the transcription factor RORyt. This report not only 
attributes a clear novel function to this only recently identified cell type in tumor immunology but also 
raises the possibility of therapeutically stimulating RORyt-dependent lymphoid tissue inducer cells in 
tumors as a new strategy for the eradication of solid tumors in patients.  
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Zusammenfassung 
 
Lymphozyten und deren sekretierten Zytokine spielen eine wichtige Rolle bei der Kontrolle und 
Eliminierung von Tumoren. In vielen verschiedenen Tumor-Modellen wurde gezeigt, dass Interleukin-
12 die Fähigkeit besitzt, das Tumorwachstum zu unterdrücken. Diese anti-tumor Aktivität von 
Interleukin-12 wird weitgehend der Aktivierung und Polarisierung von NK Zellen und Typ 1 Helfer 
Zellen zugeschrieben. Das Ziel dieses Projekts war in erster Linie das Analysieren des präzisen IL-12-
vermittelten Mechanismus welcher zur Unterdrückung des Tumorwachstums führt und nicht das 
Erforschen einer potentiellen klinischen Applizierung für eine neue Therapie. Als Model verwendeten 
wir eine Melanoma-Zelllinie (B16-F10) die stetig Interleukin-12 sekretiert. Durch systematisches 
analysieren der Immunantwort nach Injektion dieser Zelllinie in die Maus haben wir herausgefunden, 
dass die daraus folgenden Tumor-Unterdrückung unabhängig von T Lymphozyten oder NK Zellen 
erfolgt. Stattdessen konnten wir zeigen, dass IL-12 eine starke lokale anti-tumor Immunantwort 
hervorruft indem ein spezifischer Zelltyp der zur Klasse der Lymphgewebe-Induzierer Zellen gehört 
stimuliert wird. Dieser Zelltyp ist abhängigen von dem Transkriptionsfaktor RORyt. Unsere Arbeit 
beschreibt nicht nur eine klare neue Funktion für diesen erst kürzlich entdeckten Zelltyp im Rahmen 
der Tumorimmunologie, sondern erbringt auch neue Möglichkeiten für therapeutische Maßnahmen 
durch die Stimulierung von RORyt-abhängigen Lymphgewebe-Induzierer Zellen im Tumor als neue 
Strategie für die Vernichtung von festen Tumoren in Patienten.  
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Introduction 
Since the death toll from infectious diseases has declined in the western world, cancer has become 
second-ranking cause of death right after heart diseases. It affects people at all ages with the risk for 
most types increasing with age. After a quarter century of research, cancer has been revealed as a 
disease involving dynamic changes in the genome, whereby normal cells from a distinct tissue start to 
uncontrollable proliferate. Cancer refers to a malignant tumor. In comparison to benign tumors, they 
harmfully grow in healthy tissues and eventually metastasize into other tissues causing damage of vital 
structures and functions throughout the human body.  
 
 
The Properties of Cancer  
Healthy normal cells have distinct 
regulatory circuits that govern normal 
cell proliferation and homeostasis. 
Cancer cells however, clearly show 
defects in these regulations. The 
research over the past decades has 
revealed a small number of molecular, 
biochemical and cellular traits, shared 
by most and perhaps all types of 
cancer. There are specific events that 
govern the transformation of normal 
cells into malignant cancer, which are 
widely known as the ‘hallmarks of 
cancer’ (Image 1). Hanahan and 
Weinberg 1 suggested that the 
immense recording of cancer cell 
genotypes is a manifestation of six 
essential alterations in cell physiology 
that collectively dictate malignant 
growth.  
 
 
 
 
 
 
Image 1 Hallmarks of cancer 1 
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Self-Sufficiency in Growth Signals 
Signals in a cell’s surrounding, such as diffusible growth factors, extracellular matrix components, and 
cell-to-cell adhesion/interaction molecule, ensure a cell’s movement from a quiescent state into an active 
proliferative state undergoing mitosis. Without these mitogenic growth signals, no normal cell will itself 
divide. This dependency of the cell on its surrounding tissue microenvironment ensures an important 
homeostasis in normal functioning tissues. A tumor cell however, can generate many of its own growth 
signals, which act in an autocrine fashion thereby creating a positive-feedback signaling loop. Most of 
these factors not only provide growth-stimulatory signals but also sabotage the immune response 
simultaneously. Interleukin-4 (IL-4) and IL-10 for instance have been described as growth factors for 
thyroid carcinoma 2. But these two interleukins also promote the polarization of the immune response 
away from a favorable T helper (TH) 1 tumor fighting response towards a TH2 response.  Another known 
growth signal involved in the pathogenesis of prostate cancer, renal cancer and myeloma is IL-6.  IL-6 
signaling is involved in STAT3 activation thus will lead to inhibition of inflammatory responses and 
crosstalk between innate and adaptive immune responses 3, which are needed in a successful anti-tumor 
combat. Furthermore, receptor over-expression for growth signals can lead to hyper responsiveness to 
normal levels of growth signals in the surrounding 4.  
 
 
Insensitivity to Growth-Inhibitory Signals 
To further maintain a state of homeostasis, multiple anti-proliferative signals can maintain a cellular’s 
quiescence. Like the growth signals, they act through transmembrane cell surface receptors coupled to 
intracellular signaling circuits and force the cell into a state of quiescent or to permanently abandon their 
proliferative potential. Cancer cell must overcome these anti-proliferative signals mostly by disrupting the 
blockade for progression from G1 into S phase 5. Many tumors also disable components of the 
transforming growth factor beta (TGFß)-mediated signaling pathway by mutation or loss of its receptor 
and by mutation of the transcription factor SMAD4. Effector functions such as stimulation of regulatory T 
cell (Treg) proliferation, reduction of T cell proliferation, suppression of natural killer (NK) cell cytotoxicity, 
reduction of antigen (Ag) presentation by dendritic cells (DCs) and inhibition of interferon gamma (IFNγ), 
make TGFß to one of the most important anti-proliferative signals which may influence the immune 
system at different levels 6 7 8. 
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Evasion of programmed cell Death (Apoptosis) 
The extracellular and intracellular environment inspects conditions of normality or abnormality of the cell 
and influences whether a cell should live or die. Cell surface receptors bind either survival or death 
factors 9 10 and intracellular sensors detect abnormalities as DNA damage or survival factor insufficiency 
11. Two main pathways can induce the apoptotic program, the mitochondrial pathway and the death-
receptor pathway. Tumor cells however acquired resistance toward pro-apoptotic signals by means of 
over expressing endogenous inhibitors of the mitochondrial pathway like BCL-2 or MUC1. Further, they 
may lose the functional expression of factors like APAF1 that are required to induce apoptosis 12. 
 
Limitless Replicative Potential  
Cells carry an intrinsic cell-autonomous program that limits their multiplication and acts independent of 
environmental and cell-to-cell signaling. Each cell possesses at the ends of chromosomes so called 
telomeres, which are composed of several thousand repeats of a short 6 base pair (bp) sequence 
element. Each replication during a cell cycle results in a loss of 50 to 100 bp of telomeric DNA from the 
ends of every chromosome. This progressive erosion of telomeres eventually causes unprotected 
chromosomal ends leading in death of the affected cell 13. A tumor cell can overcome this senescence 
and acquired the ability to multiply without limit 14 15. Mostly they up regulate the expression of the 
telomerase enzyme, which adds hexanucleotide repeats onto the ends of telomeric DNA 16.  In addition, 
the replicative potential can be ensured by mutations in senescence-inducing proteins such as p53 12. 
 
Sustained Angiogenesis 
The vasculature supplies the cell with oxygen and nutrients. While this supply during organogenesis is 
ensured by coordinated growth of vessels and parenchyma, angiogenesis is carefully regulated in the 
accomplished tissue. Tumors induce and sustain angiogenesis in order to progress to a larger size 17 18. 
They do so by over expression of vascular endothelial growth factor (VEGF) and / or fibroblast growth 
factor 1 (FGF1) and FGF2. All of them are crucial to overcome the state of vascular quiescence by 
mediating the ‘angiogenic switch’ 12. 
 
Tissue Invasion and Metastasis 
Cancers gain during their development the capability to generate cells that leave the primary tumor mass 
and eventually invade distant organs within the body with at least initially fresh nutrients and space. 
These metastases are the cause for 90 percent of human cancer deaths 19 and depend on all of the five 
above mentioned hallmark capabilities.  
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Cancer against the Immune System 
 
From Cancer Immunosurveillance to Cancer Immunoediting 
In the early 1900s, Paul Ehrlich first conceptualized a theory suggesting, that cancer cells frequently 
arise in the body but are recognized from the immune system as foreign and are therefore eliminated 
20. Back at that time, this hypothesis however could not be experimentally tested because so little was 
known about the molecular and cellular basis of immunity. Some 50 years later, this concept has been 
formally introduced as ‘cancer immunosurveillance’ by Thomas and Burnet 21 22. They suggested that 
a cell-mediated branch of the immune system has evolved to constantly inspect the host’s tissues for 
invading pathogens and aberrant cells. Along with this theory, there had to be distinctive structures on 
tumor cells recognizable by the immune system. Many experiments followed aiming to test whether 
hosts with impaired immune systems would show evidence for increased incidences of spontaneous 
or chemically induced tumors (reviewed in Dunn et al. 2002 23). However, these studies were 
inconclusive and failed to prove or disprove the immunosurveillance hypothesis. New technologic 
advances in mouse genetics and monoclonal antibody production allowed new studies in the 1990s 
revitalizing and ultimately validating the cancer immunosurveillance concept (reviewed in Dunn et al. 
2004 24). 
It is likely that immunity generally prevents the formation of cancer in healthy individuals, but cancers 
clearly develop spontaneously in spite of this surveillance. The interaction between the immune 
system and tumors is obviously more complex than initially conceived. There has been growing 
recognition that immunosurveillance represents only one dimension of the complex relationship 
between the immune system and cancer 23 25. Whereas the immune system on one hand eliminates 
cancer cells, it also sculpts the immunogenic phenotype of tumors that eventually form in 
immunocompetent hosts and evade immune control. It has been shown, that the immune system also 
functions to promote or select tumor variants with reduced immunogenicity, thereby providing 
developing tumors with a mechanism to escape immunologic detection and elimination. These dual 
opposing functions of immunity are named "cancer immunoediting", a process consisting of three 
phases: elimination (also known as immunosurveillance or protection), equilibrium (persistence) and 
escape (progression) (Image 2) 26 25 24 27 12.  
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Image 2 The three E’s of cancer immunosurveillance 23 
Cancer immunoediting covers three processes. (a) Immunosurveillance actually corresponds 
strictly speaking only to the phase of elimination, where the immune system actively fights the 
cancer. (b) During the equilibrium phase, eventually the immune system gradually selects 
and/or promotes the generation of tumor cell variants with increasing capabilities to survive 
immune responses. (c) Ultimately, these variants might escape the immune attacks and 
expand in an uncontrolled manner. Grey = non-transformed cells / blue = developing tumor 
cells / red = tumor cell variants / orange = additional tumor variants resulting of the 
equilibrium phase / small orange dots = cytotoxic activity of lymphocytes against tumor cells / 
green = NK cells / brown = NKT cells / yellow = CD8+ T cells / purple = CD4+ T cells. 
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Elimination 
Elimination represents the classical phase of immunosurveillance. Until now, a great amount of 
research has clearly proofed the concept that deficiencies in key immunologic molecules enhanced 
the host susceptibility to both chemically induced and spontaneous tumors 26 28 29 30 31 32 33 34. But what 
is the mechanism behind the extrinsic tumor suppressor to protect the immunocompetent host from 
the development of neoplasia? Numerous studies demonstrated that lymphocytes of both the adaptive 
and innate immune compartments prevent tumor development (reviewed in Loose and Van de Wiele 
2009 35). Recently, there has also been evidence for the involvement of myeloid cells such as dendritic 
cells (DC) 36 and macrophages 37 38 39 40.   
It is a common concept of the antitumor immune response, that the innate part of the immune system 
becomes alert to the presence of a growing tumor probably through stroma remodeling and the 
resulting tissue disruption which might produce pro-inflammatory molecules 24. This molecules and 
probably molecules produced by the tumor cells themselves recruit a first line of defense to the tumor 
mass including NK cells, Natural killer T (NKT) cells, gamma delta T (γδT) cells and macrophages.  
 
Natural killer cells 
NK cells belong to the innate lymphocytes and can in contrast to T cells without Ag sensitization or 
clonal expansion, lyse NK-sensitive tumor targets41.  Their production of cytokines may also modulate 
DC and cytotoxic T lymphocyte (CTL) maturation. NK cells simultaneously express an array of 
receptors that are categorized as either activating or inhibitory. Inhibitory receptors recognize major 
histocompatibility complex (MHC) class I molecules and other cell-surface molecules, essentially 
setting the threshold for NK cell activation. Important inhibitory NK cell receptors are members of the 
KIR family in humans and the C-type lectin-like Ly49 receptors in mice. Several of the activating 
receptors recognize MHC class I-like molecules that are encoded by pathogens and expressed on 
pathogen-infected cells or that are expressed only in the context of infection, DNA damage or stress. 
Natural cytotoxicity receptor (NCRs), including NKp46, are the major activating receptors 42 43 44 45. 
Anti-tumor activities of NK cells include direct cytolysis in a perforin/granzyme-dependent manner. 
Upon interaction with the target cell, granules containing perforin and granzyme release their content. 
While perforin creates pores into the plasma membrane of the target cells, granzyme enters the cell 
and cleaves precursors of caspases leading to apoptosis of the target cell.  Further, NK cells can 
activate other immune cells through secretion of IFNγ and other cytokines. It has been shown that 
depletion of NK cells following anti-asialo-GM1 treatment results in the mouse being more prone to 
developing chemical carcinogen 3-methylcholanthrene (MCA) -induced tumors than their wild-type 
counterparts 46. 
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Natural Killer T cells  
NKT cells belong to the T cell pool but have additionally some unique features. They not only express 
a fully functional αß T cell receptor (TCR), though with a highly biased TCR repertoire, but also NK cell 
receptors. They are quite unusual in their MHC restriction as well, since they depend on a non-
classical MHC molecule, CD1d, which preferentially presents glycolipids 47. This CD1d-restricted NKT 
cell population has been divided into two subsets – type I NKT cells and type II NKT cells. Type I NKT 
cells have been characterized by a unique TCR Vα14Jα18 chain in the mouse and a Vα24Jα18 chain 
in the human along with a small number of possible TCR Vß chains. They recognize the glycolipid α-
galactosylceramide (αGalCer).Type II NKT cells on the other hand, have a diverse TCR and do not 
respond to αGalCer, but still recognize lipids presented by CD1d 48. There is yet another population of 
cells classified as NKT-like cells. Unlike the other two, they are restricted to classical MHC class I and 
II molecules but not the CD1 molecule and are therefore also termed CD1d-independent NKT cells 47, 
but will be here no further discussed. Upon stimulation, CD1-dependent NKT cells respond with a vast 
production of cytokines including IL-4, IL-10, IL-13 as well as IFNγ and Tumor necrosis factor alpha 
(TNFα) 49. Depending on the activation, NKT cells can polarize the immune response in a TH1 or TH2 
direction. Regarding the tumor immune response, activated NKT cells have been shown to mediate 
direct cytotoxicity in a perforin-dependent manner or stimulate NK cell and CTL antitumor cytotoxicity 
by the production of IFNγ. Indeed, Jα281-/- mice lacking a large population of Vα14Jα281- expressing 
invariant NKT cells, were found to develop MCA-induced sarcomas at a higher incidence than their 
wild-type counterparts 50. On the other hand it has been shown, that NKT cells polarize the anti-tumor 
immunity in a less favorable TH2 response. While type I NKT cells have been more often associated 
with tumor suppression, type II NKT cells have been shown to be involved in surveillance suppression 
51 47.  
 
Gamma delta T cells 
While most T cells express the TCRαß, a minority of 1-10 percent bears the TCRγδ, which are 
predominantly CD4-CD8-. Most of these cells are found in the intraepithelial lymphocyte (IEL) 
compartments of the skin, intestine and genitourinary tract. Even though the γ and δ TCR loci just like 
the α and ß ones may generate a vast degree of TCR diversity, only very little diversity is found in this 
type of T cells. Furthermore, these cells have Ag recognition properties fundamentally different from 
those of αß TCRs. They are not constrained by the selectivity and restriction of the MHC and therefore 
do not require peptide recognition and priming. The γδTCR structure is more similar to 
immunoglobulins (Ig) than it is to the αßTCR and has the potential to recognize a wide variety of Ags. 
Like NK cells they broadly recognize and immediately respond to cells that are missing self-
recognition or are stressed/transformed. Via perforin/granzyme, they eventually perform a direct killing 
of the transformed cells or the early IFNγ production may stimulate NK cell and CTL antitumor 
cytotoxicity 52 53. Studies in TCRδ-/- mice, showed an increase susceptibility to tumor formation and a 
higher incidence of papillomas-to-carcinoma progression compared to wild-type mice 54. 
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Macrophages 
Another player of the innate immune system are macrophages. They are capable of ingesting and 
digesting exogenous Ags, such as whole microorganisms, insoluble particles and endogenous matter, 
such as injured or dead host cells and cellular debris. The uptake of particulate Ag is an initial stimulus 
to activate the cell. However, the activity is often enhanced by secreted cytokines within their 
microenvironment, especially IFNγ. Apart from their cytotoxic activity through reactive oxygen 
intermediates (ROIs), reactive nitrogen intermediates and lysozymes, they are also potent Ag-
presenting cells (APCs) and are able to secrete various cytokines, such as IL-1, TNFα an IL-6 which 
mostly promote inflammatory responses. Recently, there has been evidence, that micro environmental 
cytokines may polarize macrophages toward a so-called M1 or M2 phenotype, whereby each 
expresses specialized functional properties. IFNγ and microbial molecules as LPS induce activation of 
M1 macrophages, which can support a TH1 immune response, microbicidal activity, immuno-
stimulatory functions and tumor cytotoxicity. IL-4, IL-10, IL-13 and colony stimulating factor (CSF-1) in 
association with either IL-1R or TLR ligands on the other hand induce M2 macrophage activation and 
promote a TH2 response, scavenging ability, promote tissue repair, angiogenesis, tissue remodeling 
and repair, which ultimately supports tumor progression 55. 
Monocytes circulating in the blood will eventually further differentiate and lead to tissue specific 
macrophages, in the case of tumors they are called tumor-associated macrophages (TAM). 
Macrophages are often the most abundant immune cell population in the tumor microenvironment. 
These TAMs within tumor microenvironment tend to polarize towards a M2 phenotype supporting the 
tumor growth by the selection of a less favorable TH2 anti-tumor response and the induction of 
angiogenesis 56. 
 
Dendritic cells 
DCs belong to the innate immune system and represent a heterogeneous population of cells defined 
by their anatomic distribution, phenotype, mode of Ag presentation and cytokine production profile. 
They not only instruct T and B cells, but also activate NK cells and produce interferons, thus linking 
the innate and adaptive immune system. Recently, there has been evidence for a novel DC subset 
which shows some unique phenotypic and functional properties 36. Expression of markers such as 
CD11c and MHCII clearly relates to conventional DCs. However, they also express markers of the NK 
cell lineage such as B220 and NK1.1 and also inhibitory (Ly49 family members, NKG2A and KLRG1) 
as well as activating (NKG2D) receptors. Apparently this novel subset of DCs has not only Ag 
presenting skills but can also exert direct cytotoxic activity against cancer cells in vitro and in vivo and 
have therefore been termed killer DC (KDC) 57 58 59 60 61. There have been different killer-mechanisms 
associated with KDC including perforin/granzyme-mediated 57 as well as TRAIL-dependent killing 62. 
KDCs may not only participate in the effector phase of the immune response eventually leading to 
tumor elimination but also promote the release and immediate availability of tumor Ags in order to 
present them to T cells. 
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Beside the direct killing of a proportion of the tumor by the innate immune cells, a common outcome of 
the innate immune system encountering the tumor mass is the production of IFNγ which leads to the 
local production of chemokines that in turn recruit more cells of the innate immune system. IL-12, here 
most likely produced by tumor-infiltrating macrophages stimulates again the IFNγ production by these 
recruited innate cells, leading to a positive feedback loop boosting the immune response. 
Furthermore, this enhanced IFNγ production may already kill a certain amount of the tumor through 
different IFNγ-dependent processes like anti-proliferative, pro-apoptotic and anti-angiostatic effects 24. 
There are several studies with support the notion, that endogenously produced IFNγ protects the host 
against the growth of transplanted tumors and spontaneous tumors 29 28 33 34 26.  
Since tumor cells arise from the body’s own cells, there clearly must exist tumor-derived immunogenic 
molecules that are qualitatively different form normal self-molecules in order for the immune system to 
elicit an effective immune surveillance. This combat of tumor cells may rely on tumor-specific Ags or 
other tumor Ags, like products of oncogenes or mutated tumor suppressor genes which can be shared 
by different cancer cells that potentially stimulate immune responses 63 64. These tumor Ags are 
probably liberated by the effect of the innate immunity. DCs now may acquire these tumor Ags and 
migrate to the draining lymph node (LN), where they induce the activation of naïve tumor-specific 
adaptive immunity 24. Until now, there have been lots of immunogenic human tumor Ags identified and 
segregated into the following classes: Differentiation Ags (e.g. melanocytes differentiation Ag, Melan-
A/MART-1, tyrosinase, gp-100), Mutational Ags (e.g. abnormal form of p53), Over expressed / 
Amplified Ags (e.g. HER-2/neu), Viral Ags (e.g. EBV and HPV) and Cancer-Testis (CT) Ags (e.g. 
MAGE, BAGE, GAGE) 65 66. But transformed cells may over express other molecular signpost through 
which they can be recognized by the adaptive as well as the innate immune system. One important 
molecule that has come up in several studies is the NKGD-activating receptor expressed on NK cells, 
γδT cells as well as CTLs. Different ligands of this receptor have been described to be expressed by a 
variety of tumors in humans and mice 25 
 
T lymphocytes 
T cells belong to the cellular branch of the adaptive immune system. They arise in the bone marrow 
and migrate for maturation to the thymus. These naïve T cells express a unique cell surface antigen-
binding molecule called the T cell receptor (TCR). Once encountering their antigenic peptide in context 
of MHC presentation, the presence of co-stimulatory signals (such as CD28-B7 interactions) and an 
additional set of cytokine signaling, they become activated. Class I and Class II MHC molecules 
interact with different co-receptors, CD8 and CD4 respectively, which allows the identification of CD4+ 
TH cells and CD8+ CTLs. CD8+ T cells, are referred to as CTLs given their ability to kill target cells or in 
this case tumor cells. They are capable to detect quantitative and qualitative antigenic differences in 
transformed cells. Differentiation of the CTLs leads then to the formation of modified lysosomes 
stuffed with perforin and granzyme and furthermore to an increased expression of death-activator-
designated Fas-ligand (Fas-L) 67 68. Upon interaction with the target cell, the lysosomes perform 
exocytosis and releases perforin and granzyme leading to perforation of the target cell and apoptosis. 
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More often however, apoptosis of the tumor cells is induced by the interaction of Fas-L with Fas. 69. 
The binding triggers apoptosis through the classical caspase cascade 70. Further, CTLs may influence 
target cells by the secretion of cytokines as TNFα or INFγ. TNFα engages its receptor on the target 
cell and triggers the caspase cascade, leading again to target-cell apoptosis. IFNγ induces 
transcriptional activation of the MHC class I Ag presentation pathway and Fas in target cells, leading 
to enhanced presentation of endogenous peptides by MHC class I and increases Fas-mediated target-
cell lysis. CD4+ T cells can be divided into TH1 and TH2 cells. The balance between these subsets has 
been shown to be critical in various immune responses, including antitumor immune responses. TH1 
cells produce mainly IFNγ. They are essential for the induction of cellular immunity. TH2 cells on the 
other hand produce IL-4, IL-5 and IL-10 and play a key role in humoral immunity counteracting the 
TH1-cell response. In terms of tumor immunity, Nishimura et al. showed that TH1 cells induced a strong 
lymphocyte infiltration into the tumor mass and eradicated the tumor via cellular immunity. TH2 cells on 
the other hand seemed to induce inflammatory responses at the tumor site and induced tumor 
necrosis 71. Even though CD4+ T cells have been shown to be sufficient by themselves in eliminating 
tumor cells in the absence of CTLs, more often however tumor-cell elimination requires both types of T 
cells 72 73 74 75. Studies with mice lacking the recombinase activating gene (RAG) and therefore can not 
produce T cells, B cells nor NKT cells, showed upon MCA-induced sarcoma faster and greater 
frequencies of tumor development 26.  
 
 
Taken together, these data not only highlight roles for both innate and adaptive immune components 
in the elimination phase of cancer immunoediting but also underline the complexity of the host’s 
immune response to developing tumors.  
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Equilibrium 
Equilibrium is the period of immune-mediated latency after incomplete tumor destruction in the 
elimination phase. This period in the course of the immune system / tumor interaction probably occurs 
prior to the detection of clinically apparent tumors. It is perhaps the longest of the three phases and 
may occur over many years in humans 76. 
Initially, the immune system constrains the growth of tumors. But basically, a productive antitumor 
immune response can serve as a biological selective pressure that promotes the emergence of more 
aggressive tumor variants. Heterogeneity and genetic instability of cancer cells is possibly the principal 
force to generate new populations of tumor cells carrying mutations, which in time might lead to 
reduced immunogenicity. Ultimately, this dynamic interaction between immunity and cancer might 
eventually lead to tumor cells with resistance to the host’s immunological blockade and therefore to 
escape. The enormous plasticity of the cancer cell genome is thought to arise from several types of 
genetic instability, including nucleotide-excision repair instability, microsatellite instability, and 
chromosomal instability 77, the latter of which may induce gains or losses of whole chromosomes.  
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Escape  
Escape refers to the final outgrowth of tumors that have overcome immunological restraints of the 
equilibrium phase. This failing in consequent detection and removal of malignant cells is the result of 
various escape strategies established by tumor cells and basically refers to the 7th hallmark of cancer. 
Since adaptive as well as innate components of the immune system play its part in cancer 
immunosurveillance, tumors most likely would have to circumvent either one or both arm of immunity 
in order to achieve progressive growth. There are several possible mechanisms by which tumor cells 
can escape. Thus, it is likely that several of this tumor sculpting events must occur before the final 
immunogenic phenotype of malignant cell is ultimately established (reviewed in 35 78 79). 
 
Alteration in MHC class I antigen 
MHC class I Ags are essential for the presentation of peptides such as tumor-associated Ags to CTLs. 
It has been shown, most if not all types of solid tumors show loss or down regulation of all or certain 
MHC class I allospecificities on cells 80 81 82 83. This lesion in Ag processing and presentation pathways 
facilitates evasion from the adaptive immune recognition. The NK cell however shows enhanced 
activity under the condition of decreased MHC class I expression, since inhibitory signals through killer 
inhibitory receptors (KIRs) are diminished. This might compensate for the poor CTL response. But it 
has also been shown, that some leukemia cell lines up-regulate MHC class I expression, which 
delivers stronger inhibitory signals to NK cells 42. 
Antigen loss 
Tumor Ags, as any other antigenic protein, requires processing by the multi-catalytic protease 
complex, called the proteasom, in order to be presented with the MHC I complex at the cell surface of 
tumor cells 84. Immunoselection may lead to tumor variants with defective antigen-
processing/presenting machinery. This can be observed by the loss or down-regulation of MHC class I 
81 or the down-regulation of molecules involved in the Ag-processing including transporter associated 
with antigen processing 1 (TAP1) or low-molecular-mass protein 2 (LMP2) 85. Eventually this will lead 
to a compromised presentation of Ags, which are need in turn to be detectable by the adaptive 
immune system thus generating tumor cells which are poorly immunogenic.  
 
Elimination of immune effector cells 
It has been shown, that persistent triggering of the T-cell receptor can lead to a phenomenon referred 
to as activation-induced cell death (AICD) 86. The tumor tissue is a massive source of Ags that 
eventually chronically stimulate infiltrating T cells and may become exhausted leading to AICD 87. 
Further, it is a fact that tumor cells can express functional FasL and this will eventually lead to 
apoptosis of Fas-expressing tumor-specific T cells 88 89 90 91.  
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Anergy/Tolerance 
Euplastic cells are antigenic, but often weakly to non-immunogenic. Basically, they express Ag against 
which an immune response could be directed, but lack the capacity to create a pro-inflammatory 
environment necessary to sustain efficient T cell activation and clonal expansion following Ag 
recognition. DCs have been shown to play a major role in dictating whether T cell priming or tolerance 
occurs 92. For full T cell activation, a DC must not only present the Ag, but also needs to provide the T 
cells with relevant co-stimulatory signals, such as cell surface expression of a family of B7 molecules, 
as well as the production of pro-inflammatory cytokines 93 92.  In an immunosuppressive tumor 
microenvironment, inflammatory mediators may be absent where DCs may fail to express the requisite 
pro-inflammatory and co-stimulatory characteristics that are needed to induce effector-functions in the 
Ag-specific T cells. This insufficient or inappropriate Ag processing and presentation may lead to 
energy or tolerance and lead to a poor immunogenicity of the tumor 94 95.  
 
Production of immunosuppressive molecules:  
Malignant cells release soluble factors, such as immunosuppressive cytokines, prostaglandins and 
vascular endothelial growth factor, which redirect immune responses toward a favorable environment 
for growth. A wide variety of malignant cells locally secret IL-10. This favors the polarization towards a 
TH2 response resulting in a less effective local anti-tumor immune reaction 96. It has been shown that 
IL-10 production from neoplastic populations involves STAT3 activation 97 3 98. Another important 
factor with pivotal function within the immune system is TGFß. This immunosuppressive cytokine 
maintains tolerance via the regulation and suppression of lymphocytes proliferation, differentiation and 
survival. A wide variety of malignancies produce TGFß resulting in suppression of the immune system 
and inversely promotion of tumor progression 99 100.They themselves on the other hand no longer 
express TGFß receptors or have a malfunctioning in the TGFß signaling to circumvent the effects of 
TGFß on themselves 101. It has also been shown, that tumor cells may become unresponsive to IFNγ, 
caused by either the absence or abnormal function of distinct components of the IFNγ receptor 
signaling pathway 28. 
 
Induction of regulatory/suppressor cells 
Tumors may also facilitate the generation, activation, or function of immunosuppressive T cell 
populations, such as type II NKT cells 102 or Treg 103 104. Tregs have been originally identified as a 
CD4+ T cell subset comprising 5-10% of all peripheral T cells. They constitutively express CD25 that 
controls the behavior of auto reactive T cells in vivo and suppresses T cell responses in vitro. Tregs 
may block the activation of CTLs and block NK cell cytotoxicity. Studies in which Tregs have been 
depleted using an anti-CD25 mAb enabled mice to reject tumors that grew progressively in control 
mice 103 105. Furthermore, there are some studies suggesting a role of myeloid-derived-suppressor 
cells (MDSC) in tumor progression. MDSC arise from myeloid progenitor cells that do not terminally 
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differentiate into mature macrophages, DC or granulocytes (reviewed in Ostrand-Rosenberg 2010 106). 
There are two major classes, granulocytic and monocytic MDSC. Granulocytic MDSC 
(Gr1+CD11b+Ly6G+) are polymorphonuclear and contain high levels of arginase, while monocytic 
MDSC (Gr1+CD11b+ICAM-1+F4/80+Ly6C+) are mononuclear and contain both arginase and inducible 
nitric oxide synthase (iNOS). There are different ways how MDSC can suppress antitumor immunity. 
They may use a mechanism in which arginase catabolizes L-arginine. L-arginine is required for protein 
synthesis and by excessive use of it, MDSC basically empty their environment with leads to L-arginine 
deprived T cells. These T cells are deficient for the CD3ξ chain and are arrested in the G0-G1 phase 
of the cell cycle. In addition, granulocytic MDSC are able to release high levels of reactive oxygen 
species (ROS) which in turn will block T cell activation or even induce apoptosis in T cells. Monocytic 
MDSC on the other hand, can elevate iNOS and in turn generate NO. Further they are able to induce 
Tregs to disturb T cell activation. 
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Cancer Immunosurveillance in Humans 
Given that there is significant evidence supporting the existence of a cancer immunosurveillance 
process in mice the question arises whether there is a similar process in humans. One would predict 
that immunodeficient or immunosuppressed humans should show greater incidences of cancer. And 
indeed, analysis of individuals with congenital or acquired immunodeficiencies or patients undergoing 
immunosuppressive therapy has documented a highly elevated incidence of virally induced 
malignancies such as Kaposi’s sarcoma, non-Hodgkin’s lymphoma and cancers of the anal and 
urogenital tracts compared with immunocompetent individuals 107-109. However, the study of the 
incidence of cancers of non-viral origins that may take many years to develop is confounded by the 
variety of viral and bacterial infections to which these immunodeficient/immunosuppressed patients 
are susceptible and by the more rapid appearance of virally induced tumors. Nevertheless, one can 
draw upon three lines of evidence to suggest that cancer immunosurveillance indeed occurs in 
humans: (a) immunosuppressed transplant recipients display higher incidences of nonviral cancers 
than age-matched immunocompetent control populations 110 111 112 (b) cancer patients can develop 
spontaneous adaptive and innate immune responses to the tumors that they bear, and (c) the 
presence of lymphocytes within the tumor can be a positive prognostic indicator of patient survival 113, 
114 115. 
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Skin Cancer 
Cancer is generally divided into solid tumors or systemic cancer. Unlike systemic cancer diseases, 
solid tumors evolve from aberrant cells within an organ. This is the case for 95 percent of all cancer 
including skin cancer. Leukemia and lymphoma, they on the other hand evolve from the blood or 
lymph system and therefore affect the whole organism.  
The skin is the biggest 
organ of the human body. It 
belongs to a first line of 
nonspecific defense and 
protects the inner organs 
from external influences like 
heat or pressure but also 
regulates the body’s 
temperature. Composed of 
epithelial tissues it covers 
and lines our body. There 
are two primary layers: 
epidermis and dermis 
(Image 3). The epidermis is 
the outermost layer and 
contains mostly 
keratinocytes, which are 
responsible for the 
production of keratin. 
Undergoing a process called 
cornification they produce more and more keratin. Fully cornified keratinocytes that form the outermost 
layer are constantly shed off and replaced by new cells. Melanocytes are found in the bottom layer of 
the epidermis. They produce melanin, a pigment primarily responsible for the color of the skin and 
therefore block a minimal part of the UV-rays. Sometimes, clusters of melanocytes and surrounding 
tissue form non-cancerous growths called moles or nevi. Moles are very common. Most people have 
between 10 and 40 moles. The dermis is the second layer underneath the epidermis. It consists of 
connective tissue and cushions the body from stress and strain. Unlike the epidermis it harbors blood 
and lymphatic vessels, mechanoreceptors, hair follicles, sweat and sebaceous glands. The 
hypodermis is a third layer just underneath the dermis. Technically it does not belong to the skin but 
finally attaches the skin to the underlying bone and muscle, and supplies the skin with blood vessels 
and nerves. It consists of loose connective and adipose tissue.  
 
 
Image 3 Anatomy of the skin116 
The Scheme shows the anatomy of the skin with the 
epidermis, dermis, and subcutaneous tissue. Melanocytes 
are in the layer of basal cells at the deepest part of the 
epidermis. 
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In Switzerland, each year about 36000 people are diagnosed with cancer. At the same time, each year 
16000 people die from cancer. In terms of total deaths, this accounts for about 25 percent. One 
quarter of the yearly cancer incidence is due to skin cancer (excluding non-melanoma cancer) 117. But 
there is a much broader variety of skin cancer depending from what cell of the skin the cancer arises. 
Less common skin cancers are for example Dermatofibrosarcoma protuberans, Merkel cell carcinoma 
and Kaposi's sarcoma and keratoacanthoma. The Dermatofibrosarcoma protuberans is a rare 
neoplasm of the dermis layer and arises from transformed connective tissue cells and is therefore 
classified as a sarcoma. It usually behaves as benign tumor but in some cases can metastasize. The 
merkel cell carcinoma is a rare and highly aggressive cancer. Merkel cells are oval receptor cells 
found in the basal layer of the epidermis. The majority of merkel cell carcinomas appear to be caused 
in part by a newly discovered virus the merkel cell Polyomaviurs 118. Kaposi’s sarcoma is a tumor 
caused by the human herpes virus 8 119. Despite of its name, it is generally not considered a true 
sarcoma, since it arises as a cancer of lymphatic endothelium and not from transformed connective 
tissue cells. Keratoacanthoma is a relatively common low-grade malignancy that originates in the 
pilosebaceous glands and closely resembles squamous cell carcinoma.  
The three most common type of skin cancer however are basal cell carcinoma, squamous cell 
carcinoma and malignant melanoma. All of them arise from the epidermal layer of the skin 120. Basal 
cell carcinoma, the most common type, typically it is a slow growing cancer arising from cells of the 
basal layer in the epidermis and hardly every metastasizes. Chronic exposure to sunlight causes most 
of the cases. Therefore they mostly appear on forehead, nose, ears and lower lips, places the most 
exposed to the sun. People who have had one basal cell carcinoma are at risk for developing others 
over the years, either in the same area or elsewhere on the body. Squamous cell carcinoma is the 
second most common type of skin cancer. It arises from the keratinocytes forming a squamous cell 
layer in the epidermis and is also considered a slow growing cancer, which in some cases may 
metastasize. It may occur on all areas of the body including the mucous membranes and genitals, but 
are most common in areas frequently exposed to the sun. The most aggressive one is the melanoma 
(also known as black melanoma). It causes the majority of skin cancer related deaths. It is a malignant 
tumor of the skin arising from aberrant melanocytes of the epidermis. Seldom, it can appear on eye, 
meninges or mucosal membranes. The melanoma is most of the time strongly pigmented. Only a few 
melanomas produce no or only little pigments, like the amelanotic melanoma 121.  
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Melanoma  
Risk Factors for Melanoma 
There are several factors which clearly increase the risk for developing melanoma 122 123. Ultraviolet 
radiation (UVR) is the major environmental know etiologic agent associated with melanoma. In 
particular intermittent sun exposure with large blasts of UVR may promote the development of 
melanoma 124 125. Further there has been mounting evidence for the negative effects of tanning beds 
126 127. Along with the sun exposure it has become clear that the individual complexion, tanning 
abilities and extent of freckling may increase the risk of developing melanoma. Dysplastic Nevi 
however, are the strongest risk (Image 4). These atypical moles can be distinguished visually by 
clinical features of size greater than 6mm in diameter, color variegation, indistinct borders and textured 
surface. They are more likely to become cancerous than ordinary moles 128. But also a higher than 
average number of moles shows an increased risk for melanoma 129 130. The risk of developing 
melanoma may also run in the family 131. First-degree relative of melanoma patients have a higher risk 
of the disease than individuals without positive family history. This familial melanoma accounts for an 
estimated 5 to 10 percent of all cases of melanoma 132. Genetics has made it possible to identify 
genetic factors that are critical of susceptibility to melanoma 133. Pigmentation genes are known to be 
associated with melanoma, but also genetic variants in DNA repair genes are obvious candidates for 
melanoma susceptibility 134.  Furthermore, there have been few mutations found in cell cycle genes in 
the melanoma etiology 135 136.  
 
 
 
Image 4 Examples for dysplastic nevi 137 
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Types of Melanoma 
A melanoma can have different forms of 
appearance and is accordingly clinically classified 
(Image 5). The most common types are: 
superficially spreading melanoma, lentigo maligna, 
acral lentiginous melanoma and nodular melanoma 
138 139. Each subtype has a characteristic growth 
pattern and develops at favored spots on the 
human body. Superficial spreading melanoma is by 
far the most common type and is the one most 
often seen in young people. As the name suggests, 
this melanoma travels along the top layer of the 
skin for a fairly long time before penetrating more 
deeply. The first sign is the appearance of a flat or 
slightly raised discolored patch that has irregular 
borders and is somewhat geometrical in form. The 
color varies between areas of tan, brown, black, 
red, blue or white. This type of melanoma can 
occur in a previously benign mole. Lentigo maligna 
is similar to the superficial spreading type, as it also 
remains close to the skin surface for quite a while, 
and usually appears as a flat or mildly elevated 
mottled tan, brown or dark brown discoloration. 
This type of melanoma is found most often in the 
elderly, arising on chronically sun-exposed, 
damaged skin on the face, ears, arms and upper 
trunk. When this cancer becomes invasive, it is 
referred to as lentigo maligna melanoma. Acral lentiginous melanoma also spreads superficially before 
penetrating more deeply. It is quite different from the others though, as it usually appears as a black or 
brown discoloration under the nails or on the soles of the feet or palms of the hands. Nodular 
melanoma is usually invasive at the time it is first diagnosed. The malignancy is recognized when it 
becomes a bump. It is usually black, but occasionally is blue, gray, white, brown, tan, red or skin tone. 
The most frequent locations are the trunk, legs, and arms, mainly of elderly people, as well as the 
scalp in men. This is the most aggressive of the melanomas, and is found in 10 to 15 percent of 
cases. 
 
 
 
 
Image 5 Examples of melanoma 
 
 32 
Stages of Melanoma 
Classifications for melanomas are called stages. In the year 2001 a new American Joint committee on 
Cancer (AJCC) / Union Internationale Contre le Cancer (UICC) -classification and staging system for 
the malignant melanoma has been introduced (Image 6). The stage refers to the thickness (Breslow's 
thickness) and the presence of microscopic ulceration in the primary tumor, depth of penetration 
(Clark’s level of invasion), and the degree to which the melanoma has spread. This staging is usually 
used to determine treatment. While early melanomas (Stages I and II) are localized, more advanced 
melanomas (Stages III and IV) have metastasized to other parts of the body 140 141 142. 
 
This category is subdivided according to the thickness of the primary (original) tumor. 
Stage Ia The tumor is less than 1.0 mm in Breslow's thickness without ulceration 
and is in Clark's level II or III. 
Stage I 
Stage Ib The tumor is less than 1.0 mm in Breslow's thickness with ulceration 
and/or Clark's level III or IV, or it is 1.01 - 2.0 mm in thickness without 
ulceration, and may have spread to the closest lymph nodes. 
This is also subdivided according to gradations in thickness and/or depth, the presence 
or absence of ulceration, and potential regional lymph node metastases. 
Stage IIa The tumor is 1.01 - 2.0 mm in Breslow's thickness with ulceration, or is 
2.01-4.0 mm in thickness without ulceration. 
Stage IIb The tumor is 2.01-4.0 mm in Breslow's thickness with ulceration, or is 
greater than 4.0 mm in thickness without ulceration. 
Stage II 
Stage IIc The tumor is greater than 4.0 mm in Breslow's thickness with ulceration. 
Stage III Once a melanoma is known to have reached the local or regional lymph nodes, the 
disease is said to have reached Stage III. Breslow's thickness is no longer used in 
staging, but the presence of microscopic ulceration continues to be used, as it has an 
important effect on the progression of the disease. In-transit or satellite metastases are 
also included in Stage III. In this case, the spread is to skin or underlying tissue 
(subcutaneous) for a distance of more than 2 centimeters (1 cm equals 0.4 inch) from 
the primary tumor, but not beyond the regional lymph nodes. In addition, the new 
staging system includes metastases so tiny they can be seen only through the 
microscope. 
Stage IV The melanoma has metastasized to lymph nodes far away from the primary tumor or to 
internal organs, most often the lungs, followed in descending order of frequency by the 
liver, brain, bone and gastrointestinal tract. 
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Image 6 Melanoma stages 143 
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Melanoma Treatment  
Surgery to remove the tumor is the primary treatment of all stages of melanoma. And early detection 
still remains the best weapon in fighting skin cancer. Most people with thin, localized melanomas are 
cured by appropriate surgery excision 144. In addition, lymph nodes may be removed to examine 
eventual cancer spreading. Further treatment greatly depends on the diagnosed stage of the 
melanoma and includes the following treatments:  
Chemotherapy:  A number of drugs that are active in fighting cancer cells are being used to treat 
melanoma, either one at a time or in combinations. They impair cell division, which results in the death 
of rapidly dividing cells. Currently, the best single agents include Dacarbazine (DTIC), cisplatin and 
other alkylating agents 145. DTIC is however, the only chemotherapeutic agent approved by the Food 
and Drug Administration (FDA) for melanoma treatment. Treatment with DTIC (usually i.v.) leads to a 
response rate of 15-25 percent, with median response durations of 5-6 month, but less than 5 percent 
of complete responses 146. Common toxicities include mild nausea and vomiting, myelosuppression 
and fatigue. Another drug, Temozolomide (TMZ), an analog of DTIC, can be given orally and has the 
advantage to penetrate the CNS and may prevent melanoma brain metastases. In terms of response 
rate and overall survival, TMZ did not show an increase compared to DTIC. TMZ however, is very well 
tolerated and shows an advantage in terms of improvement in the quality of life. The isolation-
perfusion method is sometimes used as a pain-relieving treatment when the melanoma is on an arm 
or leg. Unfortunately, to date, the response of melanomas to chemotherapy has been limited.  
Radiation therapy: This cancer treatment uses high-energy x-rays or other types or radiation to kill 
cancer cell or keep them from growing. There are two different application types, the external radiation 
therapy or the internal radiation therapy depending on the stage and type of the cancer being treated. 
Even tough, melanoma is considered a relatively radio resistant tumor, patients may derive clinical 
benefit from radiation of symptomatic metastases 147.  
Immunotherapy: Malignant melanoma is one of the most immunogenic tumors in man; this makes it an 
attractive candidate for immunology-based anti-neoplastic cytokine-therapies. INFα is one of the few 
systemic drugs with FDA approval. IFNα has been well demonstrated to have anti-proliferative and 
immunomodulatory effects, including the inhibition of angiogenesis, the increase of MHC I Ag 
expression and the infiltration of CD4+ T cells into melanomas 146. Indeed, high-dose interferon has 
been shown to increase relapse-free survival and overall survival (OS) 148 149 150, this however not 
without substantial side effects which adversely affect the patient quality of live. Adjuvant therapy with 
lower dose of interferon have not been consistently shown to have an impact on either relapse-free 
survival or OS 151. Stage IV patients are rarely curable with standard therapy, though high-dose 
Interleukin-2 has been reported to produce durable responses in a small number of patients 152 153 154. 
IL-2, has been described to play a central role in immune regulation. It has been shown to act as T cell 
growth factor but is also capable to activate NK and B cells as well as macrophages and further 
induces the production of other cytokines such as IFNγ or TNF. In patients with systemic metastasis 
confined to one anatomic site, long-term survival is occasionally achieved by complete resection of all 
metastatic disease 155 156 157 158. However, interleukin-2 is associated with very significant side effects 
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when given in high doses 146 and requires hospitalization with intensive monitoring. Major toxicities 
include fever, chills, hypotension, increases capillary permeability, cardiac arrhythmias, oliguria, 
volume overload, delirium and rash. Combination of cytotoxic agents with IFNα and/or IL-2 in 
biochemotherapies however, has demonstrated promising antitumor activity.   
There are a variety of new treatments being tested in mouse models as well as in human trials: 
Vaccine therapies: The vaccines are intended to stimulate the immune system so that it reacts more 
strongly against a patient's melanoma cells, destroying the cancer or slowing the progression. These 
strategies include vaccination with peptide, DCs, nucleic acids and het shock protein complexes. 
Adoptive cell therapy (ACT): ACT involves the harvesting of lymphocytes from the patient, in vitro 
selection/expansion/activation and subsequent infusion of processed lymphocytes back into the 
patient to induce an immune response against the cancer cells 147.   
Monoclonal antibody therapy (Targeted therapy): One option is the treatment with Anti-cytotoxic T-
lymphocyte Ag (CTLA)-4 antibodies (ipilimumab and tremelimumab). CTLA-4 is expressed on 
activated T cells and acts as negative regulator of T cell activation and Ab against CTLA-4 may 
potentiate immune responses against cancer cells 147.  
Anti angiogenic therapy: They are anti-angiogenic, which means that they prevent new blood vessels 
from forming and therefore cut off the blood supply that would otherwise nourish the cancer cells and 
enable them to grow. These drugs are still experimental and a good deal of research into improving 
and combining them with others is going on. Studies are underway with the anti-angiogenic drug, 
thalidomide, combined with the chemotherapeutic agent, temozolomide. Angiostatin and endostatin 
are two other drugs in this class that have shown some degree of activity against melanoma in 
preliminary studies 
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B16 – a Mouse Model for Melanoma 
Several syngeneic transplantation models for melanoma exist in common mouse strains, including the 
Harding-Passey Melanoma in BALB/cxDBA/2F1 mice 159 or the Cloudman S91 melanoma in DBA/2 
mice 160. The most frequently used syngeneic murine melanoma model is however B16 derived from a 
spontaneously arising melanoma of C57BL/6J origin 161. It is regarded as a poorly immunogenic 
model, since B16 melanoma expresses rather low level of MHC I class molecules therefore hampering 
the recognition by CTLs. Nevertheless, B16 melanoma cells express some melanoma-associated Ags 
such as Tyrosinase-related protein-2 (TRP-2) or gp100 and immunotherapeutic interventions 
(including cytokines) could induce tumor regression suggesting some immunogenicity of B16 tumors 
162 163. One of the thoroughly tested cytokines within the B16 model is IL-12.  
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Interleukin-12  
The cytokine interleukin 12 (IL-12) was 
originally identified as a NK cell–stimulatory 
factor 165 and is produced mainly by activated 
antigen-presenting cells 166 particular by DCs 
and macrophages, although it can also be 
secreted by PMNs. IL-12 is a heterodimeric 
cytokine of 70 kDa consisting of heavy (p40) 
and light (p35) subunits, which are covalently 
linked (Image 7) 167 168 169. While p40 appears 
to be produced in abundance in these cell 
types, the production of p35 is ubiquitously 
and constitutively expressed only at low 
levels and it requires p40 co-expression for 
secretion of the biologically active cytokine 
from the cell 170. IL-12 is mostly secreted 
upon TLR activation and it therefore acts as 
an early pro-inflammatory cytokine in 
response to many infectious agents 171. The 
most physiologically important IL-12 targets 
are conventional NK (cNK) cells, NKT cells 
and T cells, in which IL-12 induces 
proliferation, the expression of cytotoxic 
mediators, and the production of cytokines, 
most importantly IFNγ, but also GM-CSF, 
TNF and IL-2 that are necessary for the ensuing immune response; it drives further production of IL-12 
from DCs and macrophages in a positive feedback loop and finally it drives the differentiation of naïve 
T cells to an IFNγ-producing TH1 effector cell phenotype 172. Thus, IFNγ is an important mediator of 
the effects of IL-12. Furthermore, IL-12 favors the differentiation toward TH1 cells 164, which are 
thought to yield superior antitumor immunity 71. IL-12 signals through the heterodimeric IL-12 receptor 
(IL-12R) that is formed by IL-12Rβ1 and IL-12Rβ2 subunits and which predominantly bind to p40 and 
p35 chains, respectively 173. Co-expression of both subunits is required for the generation of high 
affinity binding sites for p70 binding and IL-12Rβ2 is the critical signal transducing subunit of the 
receptor complex 174. Triggering of the receptor activates the JAK-STAT signaling pathway, with 
STAT4 being the predominant mediator of cellular responses activated by IL-12. The IL-12R is 
predominantly found on NK cells and activated T cells but it has also been demonstrated on the 
surface of APCs implying an autocrine effect 175 176. The expression of IL-12Rβ2 on TH1 cells is tightly 
regulated with its expression being maintained by IFN-γ and T-bet expression and inhibited by the TH2 
cytokine IL-4. 
 
 
Image 7 IL-12 Signaling-Complex 164 
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Interleukin-12 in Tumor Immunology 
It is held that an array of different immune cells interacts with tumor cells from the earliest stages of 
malignant transformation to the terminal phase of widespread metastasis. These immune-tumor 
interactions are largely controlled and guided by cytokines produced by leukocytes. Several studies 
have shown that exogenously administered IL-12 impairs the growth of different tumors in vivo in 
natural as well as in therapeutic conditions 177 178 179. Boggio et al. for instant showed that in transgenic 
mice expressing the rat HER-2/neu oncogene under the transcriptional control of mouse mammary 
tumor virus (MMTV) showed spontaneous tumors in mammary glands. HER-2/neu oncogene is also 
expressed in a substantial proportion of human mammary carcinomas. The application of IL-12 in 
these mice was able to prevent tumor growth 180. Another model for spontaneously arising tumors is 
the SV11 mouse. These SV40 large T Ag transgenic mice show spontaneous tumor development in 
the choroid plexus in the brain. Again, IL-12 treatments lead to more slowly growing tumors than in 
control mice and in some cases tumors were even reduced in size 181. Noguchi et al. showed that the 
IL-12 anti-tumor effect also held true in the subcutaneously MCA induced tumor. IL-12 again was able 
to delay tumor appearance and depending on the dose of IL-12 and MCA, also reduced tumor 
incidence 182. Mice lacking the IL-12 specific subunit p35 developed significantly increased numbers of 
papillomas compared to wild type mice. And MCA-induced fibrosarcomata in Il12p40-/- mice showed 
significantly faster tumor appearance in about twice as many mice than in wt mice 50. Also, the B16 
melanoma tumor volume of mice lacking IL-12Rβ2, which specifically binds to p35, is increased 
compared to the tumor volume of wild type mice, supporting the notion that IL-12 represses tumor 
growth under normal conditions 183. The anti-tumor activity of IL-12 is however very complex and uses 
effector mechanisms of both innate resistance and adaptive immunity. The host of the data in the field 
suggests that adaptive immune responses mediated by IL-12 induced TH1 cells are responsible for the 
elimination of tumors and suggest that IL-12 lowers the threshold for T cell activation to recognize 
tumor Ag. Nevertheless, apart from this widely held notion, there is a body of literature, which 
suggests that specific recognition of tumor Ags might not always be required for the effect of IL-12 184. 
Further, this finding is contradicted by Kodama et al. 185, who showed that IL-12 still represses growth 
of B16 melanoma cells in Rag2-/- mice, lacking T cells. Also Boggio et al. showed that in the 
spontaneous tumor model of rat HER-2/neu oncogene expressing mice, IL-12 administration was still 
able to prevent tumor growth, even when mice were thymectomized at 4 weeks and treated with anti-
CD8 mAb 180. The seminal work by Smyth and colleagues demonstrates that NK and NKT cells 
contribute to the natural protection from tumor metastasis in the B16 model 31. In Jα281-/- mice, which 
lack the invariant Vα14Jα281 TCR and therefore lack Vα14 NKT cells exclusively, IL-12 application 
could no longer suppress metastasized B16 in the liver after intra splenic injection compared to wt 
mice. In contrast, in Rag-/-Vα14NKT mice, which exclusively generate Vα14 NKT cells, IL-12 
treatment lead to fully rejected metastasis. Similar results were obtained from B16 subcutaneously 
injected 186. Supporting these findings, Nakagawa et al. showed, that αGalCer, the specific ligand for 
the Vα14Jα281 NKT cells, as well as its synthetic homologue KRN7000, proofed to be a natural 
inducer of IL-12 and has the ability to induce anti-tumor immunity in mice 187. Tallying these findings, 
KRN700 in C26 hepatic metastases clearly showed that αGalCer activity is IL-12 dependent since it is 
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abrogated in Il12p40-/- mice 188. The experiments of Kodoma et al. with Rag2-/- mice, lacking not only 
T cells but also NKT cells, did not support a role of NKT cells in IL-12 anti-tumor activity. They on the 
other hand propose that conventional NK (cNK) cells are critical, since the IL12-inhibited lung 
metastasis effect in Rag2-/- mice was abolished when NK cells were depleted. Further, the IL-12 
effect was abrogated by perforin deficiency but not by FAS ligand deficiency 185. This discrepancy 
seemed to depend on the dose of administered IL-12. While high-dose IL-12 seemed to mediated anti-
tumor activity by NK cells and perforin, low dose of IL-12 suggested a partial role for NKT cells 31. And 
to make it even more complex there were studies suggesting, that other γc-dependent non-T non-B 
cells, possibly lymphoid DCs, are activated by the IL-12-mediated rejection of subcutaneous tumors, 
since NK cell depletion in Rag-/- mice did not alter the IL-12 mediated effect 189. Watkins et al. even 
showed that IL-12 was able to reprogram the functional profile of tumor-associated macrophages 
(TAMs) that had been chronically polarized in their function by the tumor environment of Lewis Lung 
Carcinoma (LLC) 40. It was suggested that the site of implantation of the tumor critically affects the 
nature of the cell types recruited by IL-12. NK cells seemed to be involved in the IL-12-mediated 
rejection of liver metastases, whereas other γc-dependent probably DCs, were required for rejection of 
skin tumors 189. In spite of the fact that most of the above mentioned studies use the same tumor 
model, namely growth of B16 melanoma cell lines under the skin or metastasis formation of these 
cells in the lung and liver, they each propose a different mechanism of how IL-12 represses tumor 
growth in mice. 
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IL-12 in Cancer Therapy 
The effective treatment of tumor and its metastases is a challenge for any cancer treatment. Many 
have clearly demonstrated that IL-12 is an effective and promising antitumor cytokine. Unfortunately, 
preclinical and clinical trials using systemic administration of recombinant IL-12 demonstrated severe 
adverse side effects and only to some extend tumor regression. Early studies tried to evaluate the 
safety of subcutaneously (s.c.) and intravenously (i.v.) injected IL-12. A phase I trial with i.v. injection 
of IL-12 was performed on patients with advanced malignancies including renal cancer, melanoma 
and colon cancer. IL-12 (500ng/kg dose level = maximum tolerated dose (MTD)) was first 
administered once as an inpatient. After 2 weeks of rest, the patient received one injection daily for 5 
days in every 3 weeks as an outpatient. Injection was followed by common toxicities including fever 
/chills, fatigue, nausea, vomiting, and headache. Furthermore, anemia, neutropenia, lymphopenia, 
hyperglycemia, thrombocytopenia, and hypoalbuminemia were observed. Unfortunately there was 
only a partial response to IL-12 (renal cancer) and one transient complete response (melanoma) 190. 
The phase II trial with i.v. administered IL-12 (500nk/kg dose level) based on the phase I trial by Atkins 
et al. however resulted in severe toxicities. Of the 17 patients receiving IL-12, 12 patients were 
hospitalized and 2 patients died 191. Another Phase I trial with i.v. injected IL-12 twice weekly, some 
partial clinical responses and stable disease were observed in patients with metastatic renal cell 
cancer or malignant melanoma 192. The clinical trial of Hurteau et al. tried to use a pre-dosing 
approach to limit the toxicity. Patients with recurrent or refractory ovarian cancer received i.v. injected 
IL-12 (250ng/kg) as a single dose on day 1, followed by a 2-week rest period and subsequent cycles 
of daily administration for 5 days with 16 days rest in between the cycles. One patient was a partial 
responder and 13 patients out of 26 had stable disease. 21percent of the patients developed grade 4 
myelotoxicity while two patients had capillary leak syndrome 193. Early studies from Bajetta et al. 194 
evaluated the safety profile of s.c. administered recombinant human IL-12 (rHuIL-12) and its antitumor 
effect in metastatic melanoma. They showed that the IL-12 treatment was tolerated, albeit again not 
without toxicity consisted of a flu-like syndrome including fever, chills, fatigue and arthromyalgias and 
some patient specific abnormalities concerning pulmonary toxicity, hyperfibrinogenemia and anemia. 
The fixed dose given at three time points during two identical 28-day cycles lead to tumor shrinkage 
involving regression of s.c. nodules in 3 out of 10 patients. However, while circulating IL-12 peaked 8-
12 h after the first injection, levels dropped below detectable values 24-30 h after drug administration, 
therefore the repeated administration. This repeated administration of rHuIL-12 however lead to an 
anti-IL-12 immune response that progressively inhibited the diffusion of rHuIL-12 into the bloodstream 
or lead to more rapid clearance of rHuIL-12 from the blood. This unprecedented phenomenon could 
not be explained on the basis of an antibody response to the injected cytokine. Phase I studies of s.c. 
administration of IL-12 by Motzer et al. and Portielje et al. in patients with advanced renal cancer 
resulted in more limited toxic effects. Escalating doses of IL-12 given on day 1,8,15 of a 28-day cycle 
showed dose-limiting toxicities like increase in transaminase concentration, pulmonary toxicity, and 
leukopenia. The most severe toxicities occurred with the first injection and were milder upon further 
treatment. 195. The pre-dosing protocol of Portielje et al. relied on a single IL-12 dose followed by a 
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three times weekly s.c. injection after 8 days of rest. Dose-limiting toxicity comprised deterioration of 
performance status, fever, vomiting, mental depression, and leukopenia. In comparison with a single 
administration, the three times weekly administrations at the same dose level were accompanied with 
a milder pattern of side effects 196. The use of gene therapy for the delivery of the cytokine was 
therefore the next focus of research to improve the antitumor treatment with IL-12. Several methods 
for the delivery of IL-12 have been tested, some of them more successful than others. A newer study 
evaluated the safety and efficacy of intratumoral application of plasmid DNA encoding IL-12 with 
patients bearing malignant melanoma with stage IV 197. The application of IL-12 DNA (three injections 
per cycle, for up to seven cycles) induced clinical responses, which lead to one complete remission 
and two stable diseases in 9 patients. Furthermore, they could detect a local response at the injection 
site in all but one of the 9 patients. An additional study confirmed these results of local intratumoral 
injection of IL-12 plasmid, however, showed that no change was seen in non-treated distant lesions 
198.  
Rakhmilevich et al. administered an IL-12 cDNA gene construct in situ into skin tissue via gene gun 
delivery which resulted in minimal side effects but conversely did not lead to an improved tumor 
regression 199. A phase I trials of IL-12 gene therapy used genetically engineered autologous 
fibroblasts in patients with advanced malignancies. Primary fibroblast cultures from patients were 
transduced using a retroviral vector carrying the huIL-12 gene. Out of 13 patients they reported 2 
reductions of tumor sizes at injection site and 2 reductions of tumor sizes at non-injection sites 200 201. 
Another treatment of tumor-bearing BALB/c mice relied on a single intratumoral injection of 
biodegradable polylactic acid microspheres loaded with recombinant IL-12 which promoted complete 
regression of the primary tumor and prevented the metastatic spread to the lung.202. The injection 
however was done at a very early time point of the tumor growth and was not shown to work also in 
later stages. Approaches with in vivo electroporation of IL-12 as gene delivery technique have also 
been tested in the B16 tumor model. The intratumoral application of a plasmid encoding IL-12 with 
following in vivo electroporations resulted in a cure of 47 percent of tumor bearing mice. Further, 70 
percent of the cured mice were resistant to challenge with B16 203, 204. A further method to deliver IL-12 
is viral-mediated. Oncolytic adenoviruses have been developed as anticancer biological agents 205. 
These conditionally replicating adenoviruses (CRAds) specifically replicate in cancer cells and kill 
these. Within a solid tumor mass for instance, the release of newly formed infectious particles from 
infected cancer cells allows additional cell layers to be infected and destroyed. Tough used as 
monotherapeutic agents, CRAds showed only limited effects in clinical trials. These CRAds have been 
used by Lee et al. to deliver IL-12 and elicit a potent antitumor effect in the B16-F10 murine melanoma 
model 206. When intratumoral injected into tumors of the size around 80 to 100mm3, tumor growth was 
significantly reduced compared to the PBS injected control group. Given that the mode of action of IL-
12-mediated tumor suppression has yet to be discovered.  
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Lymphoid Tissue inducer cells 
Fetal Lymphoid Tissue inducer cells  
In 1992, Kelly and Scollay discovered in studies with newborn mice, the accumulation of a new cell 
population positive for CD4 but negative for CD3 207 208. Being present in high numbers in the neonatal 
LN, this population did not seem to increase greatly after birth but instead rapidly diminished in 
proportion to CD3+ cell numbers. The cells seemed to have a lymphoid morphology, but their origin 
and function have not been determined at that time. Some years later, Mebius et al. 209 clearly showed 
that these CD4+CD3- cells uniformly express CD45 and thus belong to the hematopoietic system. 
However, they neither rearranged the ß chain of the TCR nor the IgH chain, and did not express pTα 
nor had detectable mRNA levels for the recombinase enzymes RAG1 and RAG2, suggesting that they 
do not belong to the T or B lymphocyte-rearranging subsets. Instead, in vitro studies suggested that 
this cell type in the presence of IL-2 had the ability to express the NK cell marker Nk1.1 and in 
response to IL-4 and GM-CSF showed potential APC skills in mixed lymphocyte reactions (MLR). In 
addition, CD4+CD3- cells expressed LTαß, IL-7Rα and IL-2Rα at high levels. About 75 percent of the 
cells further expressed IL-2Rα (CD25) and MHC II. This cell type could be found in fetal/neonatal 
lymph nodes, spleen and intestine but not in fetal liver or thymus. Mebius and others proposed that 
CD4+CD3- cells play a role in the initiation of lymphoid structure during ontogeny 209 210 211, which 
would tally with the findings of null mutations of LTα, LTß, LTßR, IL7Rα and IL2Rα chains resulting in 
the lack of LNs 212 213 214 215 216 217 218 219. Finally, two experimental approaches have demonstrated 
that CD4+CD3- cells clearly play a role in the initiation of lymphoid structures and were therefore 
termed ‘lymphoid tissue inducer’ (LTi) cells. Firstly, CXCR5-/- mice have been shown to have 
drastically reduced numbers of Peyers Patches (PP). But the PP development was restored when 
fetal wild type CD4+CD3- cells were transferred into newborn CXCR5-/- mice 220. Furthermore, Id2-/- 
mice completely lack nasopharyngeal-associated lymphoid tissue (NALT). And again, adoptive 
transfer experiment of fetal intestine CD4+ CD3- cells into Id2-/- newborn mice let to the initiation of 
NALT-like structures 221. Secondly, mice lacking CD4+CD3- cells have been shown to completely lack 
LNs and PPs 222 223. 
The phenotype of LTi cells has been carefully described 209 211. They express ligands of the tumor 
necrosis factor (TNF) family such as LTαß, TRANCE, LIGHT and TNFα, the chemokine receptors 
CXCR5 and CCR7, the adhesion molecules Integrin α4ß1, Integrin α4ß7 and ICAM-1. Moreover these 
cells are positive for CD25 (IL-2Rα), CD44, CD90.2 (Thy1.2), CD122, CD117 (c-Kit) and CD132 (γc). 
Not all LTi cells seem to express CD4. But other than this exception, the two subsets exist with 
virtually identical surface markers and quantitative patterns of gene expression 224. The proportion of 
CD4+ and CD4- LTi cells seems to vary depending on the different LNs being analyzed 224. Functional 
experiments with CD4- cells have not been done and it remains to be tested if they really do belong to 
the LTi cell pool.  
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Table 1 Phenotypic comparison of human and mouse LTi cells 225 
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Two potential progenitor of LTi cells have been described so far in fetal liver 226 227. Akashi and 
coworkers have characterized IL-7Rα+Sca-1lowc-Kitlow cells in the fetal liver with the ability to give rise 
to CD45+CD4+CD3- cells both in vivo and in vitro. And Yoshida et al. described a lin-IL-7Rα+α4ß7+ cell 
population that could differentiate into CD45+CD4+CD3- cells. The IL7Rα surface expression in the 
absence of lineage markers is a common feature these LTi progenitors share with lymphoid 
progenitors. However, the two progenitors must diverge at some earlier stage, since the LTi progenitor 
lost its B-cell potential with the expression of the integrin α4ß7+ 227. This differentiation of progenitors 
into LTi cells requires the presence of the transcription factors Ikaros 228 and nuclear retinoic acid 
related-orphan receptor RORγt 223.  The Ikaros gene encodes a family of early hematopoietic- and 
lymphocyte-restricted transcription factors. Mice with homozygous mutation in the Ikaros gene have 
only a rudimentary thymus with no definitive T cell precursors and furthermore lack LNs and PPs 228.  
As expected, RORγt deficient mice lack LTi cells and do not develop LNs and PPs. RORγt is also 
expressed by pro-inflammatory IL-17+ T helper cells and further promotes survival of double positive 
thymocytes. Latter might lead to the abnormal thymus in RORγt deficient mice 223 229 230. LTi 
development further depends on the protein Id2, since Id2 deficiency comes along with the absence of 
LTi cells and thus leads to the lack of LNs, PPs and NALT. Id proteins are inhibitors of basic helix-
loop-helix transcription factors and play an important role in the regulation of lineage commitment and 
differentiation 222. LTi cells have been shown to co-express TNF-related activation-induced chemokine 
(TRANCE; also known as RANKL) and its receptor TRANCER (also known as RANK) 231. It has been 
speculated that TRANCE mediates the differentiation of precursors towards LTi cells at the locations 
of LN organogenesis since in the absence of TRANCER signaling, LTi cells in rudimentary LNs are 
markedly reduced in numbers 231 232 233.  
Human mesentery in the first trimester and developing human LNs in the second trimester contained a 
population of Lin-CD127+RORγt+CD4- cells 225. Spits and coworkers found that these cells showed a 
similar phenotype as the LTi cell type in mice and were therefore considered to be its human 
counterpart. They further showed that the co-culturing of fetal human mesenchymal stem cells (MSC) 
with LN derived Lin-CD127+RORγt+ cells indeed induced VCAM1 expression in a TNF and LTß 
dependent manner 225.  
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The Role of Lymphoid Tissue inducer Cells in Lymph Node Organogenesis 
During embryogenesis, endothelial-cells bud from larger veins and form so called lymph sacs. Within 
these lymph sacs, clustering of IL-7Rα+ cells (inducer) with VCAM-1+ resident stromal cells (organizer) 
takes place during the early formation of LN anlagen (E12.5 and E13.5). This interaction between 
inducer and organizer cells is mediated by activated integrin α4ß1 220. Stimulation of the IL-7R 
pathway induces the expression of LTα1ß2 in LTi cells 234 which in turn eventually allows LTßR 
triggering on stromal cells. Studies in KO mice have shown that molecules of the TNF super-family are 
crucial for the development of LNs. Indeed, in the absence of LTα, LTß or LTßR, LN development is 
blocked, indicating that the engagement of LTßR is an essential step for LN organogenesis. 
Additional, injection of a LTßR agonist antibody (Ab) into LTα-/- mice is able to restore LN 
development. The stimulation of LTßR activates two NFκB pathways where as the alternative trail will 
lead to chemokine production, such as CCL19, CCL21, CXCL12 and CXCL13, generally important to 
attract T and B cells 235 236 237. CXCL13 binds to CXCR5, the corresponding chemokine receptor 
expressed by LTi cells, and leads to the activation of integrin α4ß1 220.The activated form of α4ß1 
binds to VCAM-1, thereby leading to a firm adhesion between LTi cells and organizer cells. Since mice 
deficient for CXCR5 or CXCL13 lack most LNs, it is clear that chemokine/chemokine receptor family 
members are required for LN development. The classical NFκB pathway will lead to further up 
regulation of VCAM1 expression on organizer cells and in turn causes the accumulation of more LTi 
cells and therefore a positive feedback loop on the LTßR signaling 238. Eventually a large enough 
cluster develops, and blood vessels start to differentiate into high endothelial venules (HEVs), which 
allow cells to enter from the bloodstream. Subsequently, organization into distinct B- and T- cell areas 
occurs in these organs (Image 8) (reviewed in Mebius 2003 239).  
 
 
 
Image 8 Model for lymphoid-organ development 239 
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Interleukin 7 
IL-7 is a member of the IL-2/IL-15 cytokine family and was originally discovered as a result of its 
proliferative activity on immature murine B cells in vitro 240. It is expressed by mesenchymal and 
epithelial cells in the gut, bone marrow (BM) and thymus and can also be expressed by fibroblasts, 
smooth muscle cells, keratinocytes and DCs following activation 241 242. The IL-7 receptor (IL-7R) is 
composed of the common cytokine gamma chain (γc) and the IL-7Rα chain 240 241. In mice, expression 
of the IL-7Rα chain is limited to hematopoietic cells, mostly from the lymphoid lineage. Both IL-7Rα 
and γc subunits are expressed by LTi cells. 241 242. IL-7 has been implicated in B and T cell 
development and in γδ TCR rearrangement. Further, IL-7 plays a role in survival/persistence of resting 
CD4 and CD8 T cells and their homeostatic turnover. It may also be responsible for the differentiation 
of effector to memory T cells 243 244. IL-7-deficient mice, have a blocked B cell development at the pro-
B cell stage, the thymic cellularity is decreased 20-fold, have a reduced αß T cell population, whereas 
γδ T cells are nearly absent 243. Lacking IL-7, IL-7Rα or the signaling component of IL-7R, such as 
Jak3 results in severe defects in LN and PP organogenesis in mice 245 246 216 247. Thus, IL-7 is 
important during lymphoid organogenesis. Indeed, IL-7 produced by fetal organizer cells has a key 
function in inducing LTαß expression by LTi cells 248 245. 
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Adult Lymphoid Tissue inducer Cells 
LTi cells involved in the LN organogenesis obviously can be found in neonatal mice. The question 
arises though, whether these cells are still present in adult mice. Several studies have addressed this 
issue in the past years. However, the first study was published as early as 1993 and focused rather on 
helminths infection than adult LTi cells. Nevertheless, Estes et al. showed that upon parasite infection 
with Mesocestoides corti, enriched CD4+ splenocytes from infected animals and cultured in the 
presence of the parasite, increase in terms of CD4+CD3- cells while CD4+TCRαß+ cells seemed to 
decline.  In addition, flow cytometry analysis of spleen and liver of infected mice revealed an increased 
number of CD4+CD3- cells compared to uninfected mice. It has been hypothesized that these cells 
may play a role in maintaining the balance between host and parasite 249. Almost 10 years later, 
Littman and coworkers who already proofed the requirement for RORγt in fetal LTi cells 223, showed in 
adult mice clusters of RORγt+ cells within Cryptopatches (CPs) and to lesser extent in isolated 
lymphoid follicles (ILFs) and subepithelial dome of PPs. These cells proofed to be c-kit and IL-7Rá 
positive but negative for all lineage markers except CD4. These adult intestinal RORyt cells share 
developmental, phenotypic and functional features with fetal LTi cells 230, 250. Indeed, a recent study 
showed that the reconstitution of RORyt-/- mice with bone marrow (BM) as a source for RORyt+ LTi 
cells from adult mice induced the development of organized structures in the gut 251. Also the transfer 
of wild type BM into LTα-/- or γc-/- mice allowed the reconstitution of CPs and ILFs, thus BM may be a 
source of LTi-like precursors 250 251. Adult LTi cells have also shown to be present in the spleen; more 
precise in B follicles and at the interface between the B and T cell area 252. The data showed that the 
cells here are closely associated with Ag-specific T cells during primary and memory phase of immune 
responses. High levels of OX40L (also known as TNFSF4) and CD30L (also known as TNFSF8) 
expression by CD4+CD3- cells potentially provides co stimulatory signals to primed T cells and may 
ensure that T cells are fully committed to the provision of B cell help. Adult but not fetal LTi cells 
exclusively expressed these TNF ligands for OX40 and CD30 after in vitro culture. However, addition 
of IL-7 to neonatal LTi cells increased CD30L expression 253. This lack of OX40L and CD30L 
expression on neonatal inducer cells could be a contributory mechanism for neonatal tolerance 
induction 253. Furthermore, LTi cells may be important for splenic organization, since adult CD4+CD3- 
cells transferred into LTα-/- mice were able to segregate lymphocytes into B and T cell areas, which is 
usually impaired in these mice. Due to their tight association with VCAM1+ stromal cells also in the 
spleen, they are in the position to elicit the secretion of homeostatic chemokines from stromal 
populations 252. At last, Ludewig and coworkers showed that LTi cell – stromal cell crosstalk continues 
into adulthood. Acute infection with lymphocytic choriomenigitis virus (LCMV) leads to disruption of 
lymphoid organ integrity, with the consequence that the host becomes unable to respond to pathogens 
and loses immunocompetence. Mainly the gp38+ fibroblastic reticular cell (FRC) network in the white 
pulp is affected by this disruption. After clearance of the virus however, accumulation of LTi cells in the 
spleen and LNs occurred with following re-establishment of the FRC network. In the absence of 
CD45+CD4+IL-7Rα+lin- cells, the reorganization of the spleen was delayed 254. 
Adult LTi cells also exist in humans. Cupedo et al. was able to detect them in postnatal tonsils 225.  
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NKp46+ Lymphoid Tissue inducer Cells 
 
 
 
Image 9 Localization of gut RORyt+NKp46+ cells 255  
 
 
Recent studies identified an IL-22 producing population in the gut of mice, which shares features of 
both LTi cells and NK cells and is thought to be involved in mucosal immunity (reviewed in Vivier et al. 
2009). Independent reports described this novel population in cryptopatches (CP) of the small 
intestine in mice 256 257 258 259. Just like LTi cells they express IL-7Rα and are positive for RORγt. 
However in addition they express NKp46 (also known as NCR1). NKp46 is an immunoglobulin-like 
transmembrane glycoprotein belonging to the family of natural cytotoxicity receptors (NCRs) and is 
involved in the recognition of tumor-cell targets by NK cells 260. NKp46 is therefore usually though to 
be a selective marker for both mouse and human NK cells 261. Nevertheless, there are non-NK cell 
populations described to express NKp46, like a discrete subset of γδT cells in mice 261 and 
intraepithelial lymphocyte-subsets in coeliac disease patients 262. Unlike conventional NK (cNK) cells, 
RORγt+NKp46+IL7Rα+ cells seem to develop independent of IL-15 and lack markers of mature NK 
cells. Further they don’t posses cytotoxic effector functions as perforin and granzyme and have low or 
absent IFNγ production. Instead, they have been shown to be strong producers of IL-22, in particular 
in response to IL-23 257 258. IL-22 is a member of the family of IL-10 related cytokines. It’s receptor is 
exclusively found on epithelial cells and leads when activated to the production of antimicrobial 
molecules 263 264 265 and the anti-inflammatory cytokine IL-10 266. In mice, deficiency of IL-22 leads to 
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compromised epithelial cell barrier function in the gut und subsequent spread of bacteria 265. Indeed, 
RAG2-/-IL-2Rγ-/- mice which lack NKp46+IL7Rα+NK1.1- cells, showed reduced steady-state IL-22 in the 
intestine that correlated with heightened susceptibility to Citrobacter rodentium 257. Clearly, this IL-22 
producing cell population contributes to the so far unknown source of IL-22 production in the gut.  
Splenic LTi-like cells have been shown to produce in addition to IL-22 also IL-17 267 which has been 
known to induce the production of granulopoietic factors (GM-CSF and stem cell factor (SCF)). 
Newest findings show that this just recently identified cell type accumulates in the inflamed colon of 
Helicobacter hepaticus infected mice. Depletion of this population during the course of infection 
resulted in abrogation of both colitis and typhlitis. Buonocore et al. suggested that they directly 
mediate IL-23-dependent acute and chronic innate immune-mediated colitis through the production of 
inflammatory cytokines such as IL-17 and IFNγ in response to microbes 268.  
 
 
Table 2 Expression profiles of adult NK cells, LTI cells and mucosal RORyt+NKp46+ cells 255 
 
 
 
An equivalent to this population has also been found in human tonsils and PPs. Developmentally and 
functionally, these mucosal RORC+CD127+CD56+NKp44+ cells resemble the RORyt+NKp46+ 
population found in mice 225 2269. A variety of culturing conditions allowed a robust differentiation of 
human LTi cells into these CD127+CD56+NKp44+ cells in vitro 225. As their mouse counterpart this 
population produced IL-22 especially in response to IL-23 269 and showed only minimal expression of 
perforin and granzyme 225. And like human LTi cells, this population was able to induce the expression 
of adhesion molecules on MSCs when co-cultured in vitro 225 270.  
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Despite the fact that this newly described subset expresses NKp46, their developmental dependence 
on RORγt and their specific tissue location suggest that RORγt+NKp46+ cells might represent a 
subpopulation (or descendants) of LTi cells rather than yet another NK cell subset. Two recent studies 
support this assumption in mice as well as in humans. Di Santo and co-workers found that the 
development of both, RORγt+NKp46+ cells as well as LTi cells, requires IL-7 and is independent of IL-
15. Over expression of IL-15 however clearly expanded cNK cells in vivo. Further they observed by in 
vivo cell fate mapping that cNK cells never express RORc during their development, clearly dismissing 
a RORγt+ progenitor for cNK cells 271. Crellin et al. showed that human Lin-CD127+RORc+ cells in 
tonsils are the precursors to CD56+CD127+RORc+NKp44+ cells. Together this two cell populations 
comprise a stable RORc+ lineage and can not be conversed into cNK cells ex vivo 270.  However, LTi 
cells and cNK cells themselves have been reported to be developmentally related, since mice deficient 
for Id2 lack both mature NK cells and LTi cells 222 271.  
 
 
 
Table 3 Comparison between adult NK cells, LTi cells and mucosal RORyt+NKp46+ cells 255 
 
 51 
Material and Methods 
Mice: C57BL/6 mice were purchased from Janvier. Il12rb2-/-, Rag1-/-, Rag2-/-Il2rg-/-, RorcGFP (Rorc-/-), 
Prf1-/-, ifng-/-, ifngr-/- and ltbr-/- mice were purchased from Jackson Laboratories and kept in house 
under spf conditions. Il15ra-/- mice were kindly provided by S. Bulfone-Paus (Department of 
Immunology and Cell Biology, Research Center Borstel, Borstel, Germany). RORc-cre x ROSA26-
stop-EYFP mice were kindly provided by A. Diefenbach (Institute of Medical Microbiology, University 
Hospital Freiburg, Germany). Il17a-/- mice were obtained from Y. Iwakura (University of Tokyo, Japan) 
and Il22-/- mice were provided by J.C. Renauld (Ludwig Inst. Brussels, Belgium). Mice were treated 
according to institutional animal care and use guidelines.   
Bone Marrow Chimera Generation: For the generation of bone marrow chimeras, donor mice 
were killed by CO2 inhalation and bone marrow cells were isolated by flushing of femur, tibia, radius 
and hipbones with PBS. Bone marrows cells were then passed through a cell strainer with a pore size 
of 100 mm and cells were washed with PBS. Recipient mice were lethally irradiated with 1,100 rads 
(split dose) and were injected intravenously with 12 × 106 to 25 × 106 bone marrow cells. Engraftment 
took place over 8 weeks of recovery. Animal experiments were approved by the Swiss Veterinary 
Office (10/2006; Zurich, Switzerland). 
Generation of the tumor cell lines B16–IL-12, B16–IL-23 and B16-Fc:  The parental 
B16.F10 mouse melanoma cell line (Xenogen) was stably transfected with a pCEP4 plasmid encoding 
the Fc fragment of mouse immunoglobulin G3 alone or IL-12 or IL-23 fused to that Fc fragment. The 
selection medium contained AdvMEM, 10% (vol/vol) FCS, penicillin, streptomycin, glutamine, zeocin 
(0.2 mg/ml) and hygromycin (0.25 mg/ml). Expression of the IL-12–Fc and IL-23–Fc fusion proteins 
was confirmed by enzyme-linked immunosorbent assay with anti-L-12p40 and anti-IL-23p40 (OptEIA; 
Pharmingen) and RT-PCR (immunoglobulin G3 forward, 5′-ACACACAGCCTGGACGC-3′, and 
reverse, 5′-CATTTGAACTCCTTGCCCCT-3′). 
Subcutaneous inoculation of melanoma cell line and monitoring of tumor growth: A 
total of 1 × 105 to 10 × 105 cells were injected subcutaneously into the lateral abdomen of the mouse. 
Tumor growth was monitored by measurement of two perpendicular diameters of the skin tumor by 
caliper three times a week for a period of 3 weeks. 
Analysis of lung metastasis: Three weeks after i.v. injection of B16 or B16-IL12 cells mice were 
euthanized and the lungs dissected. The lungs were immediately photographed. 
Depletion of NK cells: Mice were injected with tumor cells on day 0 as described and injected 
intraperitoneal with 200 mg anti-NK1.1 (PK136; Bio X cell) on day –1, followed by three injections per 
week with the same amount of antibody. Depletion was confirmed by flow cytometry with an anti-
CD49b (DX5). Other mice were injected intraperitoneal with 30 ml anti-GM1 (WAKO Chemicals) on 
day –1, followed by injection every fifth day with the same amount of antibody. Depletion was 
confirmed by flow cytometry with monoclonal anti-NK1.1 (PK136). 
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Proliferation assay: B16, B16-IL12 or B16-Fc cells (5000 cells/well) were plated into a 96-well plate 
in triplicates. Medium containing 0.5 mCi/ml of [3H]thymidine was added for 4 days and the 
incorporation assessed with a Filtermate Collector (Applied Biosystems) and a scintillation and 
luminescence counter. Generation of the tumor cell lines gl261-IL12 and gl261-Fc. C57/Bl6 murine 
glioma (Gl261) cells were stably transfected with a pCEP4 plasmid (Invitrogen) encoding either IL-12 
fused to the Fc part of mlgG3 or the Fc part alone. The selection medium contained Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum, 1% GlutaMaxx (Gibco) and 0.23 
mg/ml hygromycin. The resulting cell line was called GL261-IL-12-Fc or GL261-Fc respectively. The 
expression of the IL-12 Fc fusion protein was confirmed by ELISA using an antibody against the 
mouse IL-12 subunit p40 (OptEIA; Pharmingen) and rt-PCR (IgG3fw: ACACACAGCCTGGACGC 
IgG3rev: CATTTGAACTCCTTGCCCCT). 
Protein Extraction from tumor: Three weeks after s.c. injection of B16 or B16-IL12 cells mice 
were euthanized and the tumors dissected. The tumors were homogenized in the presence of lysis 
buffer of tissue Protein Extraction Reagent (TPER, Pierce) and a protease inhibitor cocktail (Complete 
Mini proteease inhibitor cocktail tablets, Roche). Tumor homogenates were then assessed for p40 by 
ELISA kit (OptEIA; Pharmingen). 
Flow cytometry: For analysis of tumor-infiltrating lymphocytes, mice were killed by CO2 inhalation 
and tumors were dissected. Tumor mass was incubated for 30 min at 37 °C in RPMI medium 
containing DNase and Liberase, then were homogenized and strained through a nylon filter with a 
pore size of 100 mm (Fisher). After centrifugation, cells were incubated with antibodies for 20 min at 4 
°C and then were acquired with a FACSCanto II (BD Pharmingen) and BD FACSDiva software and 
analyzed with FlowJo software (TreeStar). 
Histology: Tumors were isolated carefully, embedded in optimal cutting temperature compound and 
snap-frozen in liquid nitrogen. Cryosections 6 mm in thickness were air-dried for 90 min at 25°C and 
fixed for 10 min at 25 °C with acetone and were then incubated with the following primary antibodies: 
rat anti-CD4 and rat anti-CD8 (both provided by R. Zinkernagel), armenian hamster anti-CD11c (; 
Serotec), rat anti-CD11b (; BMA biomedicals), rat anti–asialo GM1 (NK cell; ;Wako Chemicals), rat 
anti-F4/80 (; BMA biomedicals), rat anti-Gr-1 (; PharMingen–Becton Dickinson), goat anti-Nkp46 (; 
R&D Systems), rabbit anti-GFP-YFP (; Abcam), rabbit anti-CD31 (; PharMingen–Becton Dickinson), 
rabbit anti-CD54 (ICAM; Serotec) and rabbit anti-CD106 (VCAM-1; Serotec). For conventional 
immunohistochemistry, antibodies were coupled to alkaline phosphatase or were detected with 
alkaline phosphatase–coupled secondary antibodies. Staining was visualized with Fast Red as the 
alkaline phosphatase substrate (Refine Detection kit; Leica). Brightfield images were acquired with a 
50× (Numerical aperture 0.9) objective on a Olympus BX41 light microscope equipped with a 
ColorView IIIu camera (Olympus) and Cell B software (Olympus). For immunofluorescence staining, 
primary antibodies were detected with secondary antibodies coupled to Alexa Fluor 488 or 
tetramethylrhodamine isothiocyanate and sections were mounted in fluorescence mounting medium 
containing DAPI (4′,6-diamidine-2-phenyl indole; Vectashield; Vector). Images were acquired with 20× 
(N.A. 0.7) and 63× (Numerical aperture 1.4) objectives on Leica SP5 confocal laser-scanning 
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microscope equipped with LAS AF (Leica application suite advanced fluorescence) 2.2.1 software 
(Leica) and were further analyzed with Imaris 7.1.1 software (Bitplane). Maximum intensity projections 
are presented. 
In vivo expansion of LTi cells: Rorc-EYFP mice were treated with á-IL-7/IL-7 complex as 
described by Schmutz et al.39. LTi cells were isolated using a high-yield pre-sort for EYFP+ followed 
by a low-pressure, high purity sort for EYFP+CD3-. 
In vitro stimulation of LTi cells: The cells were cultured on a non-confluent monolayer of OP9-
feeder cells in the presence of 10ng/ml of IL-7 with or without 2.5 ng/ml rIL-12 
for 24h.  
RNA Isolation and cDNA Synthesis: Cells were harvested and RNA isolated according to 
manufactures protocol (). For cDNA synthesis, 1-5 ìg RNA was reverse transcribed using reverse 
super transcriptase III (Invitrogen), which uses single stranded RNA to synthesize a complementary 
cDNA strand in the presence of a primer. The following components (all from Invitrogen) are mixed 
gently together in a tube and heated at 37°C for 5 min prior to adding M-MLV RT: 5X First strand 
buffer, dNTPs, DTT, random primers and Recombinant Ribonuclease Inhibitor RNaseOUT. The mix is 
then added to the RNA and incubated at RT for 10 min, 37°C for 50 min and 70°C for 15 min to 
inactivate the reaction. 
Real-time PCR Analysis: Diluted cDNA was mixed with the following components. Real-time PCR 
was carried out to analyze RNA expression of cytokines and chemokines using the following primer 
sequences: 
Statistical analysis: An unpaired two-tailed Student’s t-test was used to determine the statistical 
significance of differences. P values of less than 0.05 were considered statistically significant.  
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Results 
The Model 
B16 cell lines  
To determine the mechanistic 
underpinnings by which IL-12 
mobilizes antitumor immunity, 
we generated a melanoma cell 
lines that continuously released 
a fusion protein of IL-12 and the 
crystallizable fragment (IL-12–
Fc), IL-23–Fc or mouse 
immunoglobulin G3–Fc alone 
as controls (called ‘B16–IL-12’, 
‘B16–IL-23’ and ‘B16’ here, 
respectively). We confirmed 
secretion of IL-12 and IL-23 by 
enzyme-linked immunosorbent 
assay (Fig. 1a and b). The 
expression of the Fc-tail was 
confirmed by RT-PCR (Fig. 1c). 
The advantage of using fusion 
proteins over the recombinant 
cytokine is the improved 
pharmacokinetics 272 273 274. The 
use of these modified 
melanoma cell lines serves the 
purpose to identify the cell type 
responsive to IL-12 rather than 
to determine the therapeutic 
value of IL-12.  
 
 
 
Figure 1 Confirmation of the cell lines 
(a) and (b) Confirmation of IL-12/23 p40 secretion by (a) B16–IL-12 and (b) 
B16–IL-23 cells. Parental B16-F10 cell lines were transformed with an 
episomal expression vector (pCEP-Invitrogen) encoding IL-12–Fc, IL-23–Fc 
or IgG3–Fc alone and maintained in selective medium for four weeks. 
Expression of the fusion protein was confirmed by ELISA, which detects the 
p40 subunit of IL-12 and IL-23. Each data point represents triplicates. Data 
represent three experiments. (c) Confirmation of IgG3  by rt-PCR. 
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IL12 significantly induces Tumor Suppression  
Subcutaneous injection of 2×105 B16 cells into the lateral abdomen of wild-type mice induced a single 
solid tumor mass, reaching a size of ~300 mm2 after 21 days. Mice injected with 2×105 B16–IL-12 
cells had much smaller tumor masses than did those injected with the parental B16.F10 cell line or 
B16-Fc cells (Fig. 2a). Wild-type mice injected with control B16 cells secreting IL-23 instead of IL-12, 
however, did not suppress tumor growth (Fig. 2b). We confirmed IL-12 secretion in the tumor by 
enzyme-linked immunosorbent assay (Fig. 2c). 
 
 
Figure 2 IL-12 significantly induces tumor suppression 
(a) Repression of subcutaneous tumors in wild-type mice given subcutaneous injection of 2×105 B16.F10, 
B16–IL-12 or B16-Fc cells (n = 6 mice per group). Data are representative of four experiments. (b) Tumor 
suppression in wild-type mice given subcutaneous injection of 2x105 B16, B16–IL-12 or B16–IL-23 cells (n = 6 
mice per group). Data are representative of three experiments. (c) IL-12-p40 secretion in the tumor vs. serum 
in wild-type mice given subcutaneous injection of 2x105 B16 or B16–IL-12 cells (n = 6 mice per group). 
Tumors and sera were harvested 21 days post injection. Expression of the fusion protein was confirmed by 
anti p40 ELISA. Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 
(Student’s t-test).  
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Long-term tumor monitoring showed that the secreted IL-12 significantly (p<0.001) slowed tumor 
growth in wild-type mice (Fig. 3a). The ability of IL-12 to mediate tumor repression was not restricted 
to the melanoma model B16.F10. Subcutaneous injection of 2×106 GL261 cells, a syngeneic glioma 
cell line, expressing either IL-12–Fc or Fc alone into Rag1–/– mice resulted in similar tumor 
suppression (Fig. 3b). IL-12-mediated tumor suppression was not restricted to IL-12 secretion by 
transfected B16 cells but was also induced by systemic intra peritoneal (i.p.) application of 
recombinant IL-12 189 (Fig. 3c). 
 
 
Figure 3 IL-12 mediated suppression (long-term / GL261 / intraperitoneally) 
(a) Long-term repression of subcutaneous tumors in wild-type mice given subcutaneous injection of 2×105 
B16–IL-12 or B16-Fc cells (n = 6 mice per group). Tumor growth was monitored for 42 days. Data are 
representative of three experiments. (b) Repression of subcutaneous tumors in Rag1-/- mice given 
subcutaneous injection of 2x106 GL261–IL-12 or GL261–Fc cells mice (n = 6 mice/group). Data are 
representative of two experiments. (c) Tumor repression in wild-type mice given subcutaneous injection of 
2×105 B16 cells and treated intraperitoneally (i.p.) with PBS or recombinant IL-12 (rIL-12) on day 1, 3, 5 and 9 
after tumor injection (n = 3 mice per group). Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, 
**P < 0.01 and ***P < 0.001 (Student’s t-test).  
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Paracrine fashion of IL-12 
IL-12 could have been affecting tumor cell proliferation to mediate tumor suppression. However, B16–
IL-12 and B16-Fc cells proliferated in vitro approximately at the same rate as the parental cell line did 
(Fig. 4a). Thus, anti-hyperplasia cannot explain the repressive effect of IL-12 on B16 tumor growth. To 
investigate whether IL-12 functioned in a paracrine way on host cells, we mixed 1×105 B16 cells with 
B16–IL-12 cells at a ratio of 1:1 and subcutaneously injected the mixture into wild-type mice. Tumor 
development was diminished to an extent similar to that when B16–IL-12 cells were injected alone. 
Even an increase in the ratio in favor of B16 cells (1:2 and 1:10) did not extinguish the strong tumor-
repressive effect of the co injected B16–IL-12 cells (Fig. 4b), which indicated that the secreted IL-12 
acted in a paracrine way. That idea was further supported by the finding that B16–IL-12 cells showed 
uninhibited growth in Il12rb2–/– mice, which lack the IL-12-specific receptor subunit (Fig 4c). 
 
 
Figure 4 IL-12 acts in a paracrine way 
(a) In vitro proliferation of B16.F10, B16–Fc B16–IL-12. Cells were cultured in 96-well plates (triplicate-wells) 
and the incorporation of 3[H]thymidine monitored after 4 days. Data are representative of three experiments. 
(b) Repression of tumors in wild-type mice given subcutaneous injection of a mixture of B16 cells and B16–IL-
12 cells at a ratio of 1:1, 2:1 or 10:1 (n = 5 mice per group). Data are representative of at least two 
experiments. (c) Repression of tumors in wild-type or Il12rb2–/– mice given subcutaneous injection of 2 × 105 
B16 or B16–IL-12 cells (n = 6 mice per group). Data are representative of three experiments. Shown are the 
mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test).  
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Local versus Systemic Effect of IL-12  
To further distinguish local versus systemic effects of secreted IL-12, we subcutaneously injected 
2×105 B16 cells into the right lateral abdomen and 2×105 B16–IL-12 cells into the left lateral abdomen 
of wild-type mice. After 3 weeks, B16–IL-12 tumors showed only minimal growth, whereas B16 tumors 
on the right flank grew normally and were unaffected by the contra lateral B16–IL-12 cells (Fig. 5a). 
This demonstrates that IL-12 secretion acts locally and cannot repress the growth of tumors implanted 
at a distant site. The micro environmental effect of IL-12 suggested that it acts through the innate 
immune system rather than involving lymphocytes. Even injection of recombinant IL-12 into an 
established palpable tumor 7 d after tumor transfer significantly suppressed tumor growth (Fig. 5b). 
 
 
 
Figure 5 IL-12 acts locally 
(a) Tumor repression in wild-type mice given subcutaneous injection of 2×105 B16 cells in the left abdomen 
and 2×105 B16–IL-12 cells in the right lateral abdomen (n = 6 mice per group). Data are representative of 
three experiments. (b) Tumor repression in wild-type mice given subcutaneous injection of 2 × 105 B16 cells 
and intratumoral (i.t.) injection of PBS or recombinant IL-12 on days 7, 9, 12, 14, 16 and 19 after tumor 
injection (n = 3 mice per group). Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 
and ***P < 0.001 (Student’s t-test).  
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IL-12 Effect in Lung Metastasis 
Because B16–IL-12 cells had such a strong repressor phenotype on subcutaneously tumor growth, we 
also investigated the effect of IL-12 on tumor metastasis. We injected 1×105 B16 or B16–IL-12 cells 
intravenously into wild-type mice and, at 21 days after injection, we analyzed metastasis formation in 
the lungs. Although B16 cells formed many metastases, mice injected with B16–IL-12 cells did not 
develop lung metastasis (Fig. 6a and b), which indicated that IL-12 suppresses not only 
subcutaneous primary melanoma but also the formation of metastasis. 
 
 
 
Figure 6 IL-12 mediated repression of lung metastasis 
(a) and (b) Repression of lung  tumors in wild-type mice given intravenous injection 1x105 B16 (upper row) 
or B16-IL-12 (lower row) (n ≥ 4 mice per group). Mice were sacrificed after 21 days and lungs were analyzed 
(a) and counted (b) for the formation of metastasis. Data are representative of two experiments. Shown are 
the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test).  
 
 
IL-12 acts independent of Lymphocytes, NK cells or Myeloid cells 
CD45 Infiltration 
Histological analysis 3 weeks after inoculation showed that B16–IL-12 cells recruited more leukocytes 
to the tumor site than did B16 cells (Fig. 7a). Flow cytometry of the tumor 3 weeks after inoculation 
showed that in B16 tumors, CD45+ leukocytes represented only <10% of the total cells, whereas in 
B16–IL-12 tumors, >30% were CD45+ leukocytic infiltrates (Fig. 7b). There were significantly more 
CD8+ and CD4+ cells as well as CD11c+ and NK1.1+ cells in B16–IL-12 tumors than in B16 tumors, 
whereas there were fewer infiltrating CD11b+ cells and neutrophils (Ly6G, clone 1A8+) (Fig. 7c - i). 
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Figure 7 IL-12 elicits the recruitment of leukocytes into the tumor mass 
(a) Immunohistochemistry of frozen tumor sections obtained from wild-type mice 3 weeks after challenge 
with B16 or B16–IL-12 cells and stained with anti-CD4 (CD4), anti-CD8 (CD8) and anti–asialo GM1 (NK). 
Scale bar, 50 µm. (b) Cytofluorometry of tumor-invading leukocytes in mice treated as in a, assessed in the 
entire tumor mass after exclusion of cellular debris, dead cells and duplets, and presented as tumor-
infiltrating CD45+ leukocytes relative to CD45– melanoma cells. Each symbol represents an individual mouse; 
large horizontal lines indicate the mean and short lines the s.e.m.. (c–i) Cytofluorometry of tumor-invading 
leukocytes in mice treated as in a, presented as the frequency of infiltrating CD8+ cells (c), CD4+ cells (d), 
CD11c+ cells (e), CD11b+ (f), NK1.1+ cells (g), 1-A8+ cells (h) and B220+ cells (i), gated on CD45+ cells, in 
B16 tumors relative to that in B16–IL-12 tumors. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). 
Data are representative of two experiments with at least four mice per group (mean and s.e.m.). 
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Stroma versus Immune System 
In order to discern whether these tumor-invading leukocytes or IL-12-responsive tumor-surrounding 
stroma cells initiate tumor suppression, we generated a series of bone-marrow (BM) chimeric mice. 
BM-chimerism allows separating the genotype of the hematopoietic system from the radio-resistant 
stroma after lethal irradiation of the mouse and the reconstitution by hematopoietic stem cells 275 276 
277. For our purpose, we used irradiated wt mice and reconstituted them with IL-12Rb2-/- stem cells 
and vice versa. After engraftment, the mice were challenged with 2x105 B16 and B16–IL-12 
respectively. IL-12 was able to induce tumor suppression in Il12rb2–/– mice reconstituted with wt bone 
marrow expressing the IL-12 receptor only in the hematopoietic compartment. On the other hand, 
when the IL-12Rβ2 expression is restricted to the radio-resistant stromal compartment, the injected 
B16–IL-12 tumors showed the same tumor growth as the B16 cells (data not shown). This data 
suggests that secretion of IL-12 by the tumor activates a component of the immune system rather than 
a cell population belonging to the stroma. 
 
T / NKT cells 
IL-12 is known to play a predominant role in promoting TH1 responses; also T cells represent the 
dominant tumor-infiltrating cell type. In order to investigate the role of T cells in IL-12 mediated tumor 
repression, we analyzed the growth of B16–IL-12 in Rag1-/- mice. In agreement with Kodama et al., 
B16–IL-12 tumor growth continued to be repressed even in the absence of B, T and NKT cells 
excluding their involvement in the IL-12-mediated repression of subcutaneous tumors (Fig. 8a) 185. 
 
 
 
Figure 8 T cells, B cells and NKT cells independent IL-12-mediated repression of subcutaneous tumor  
 (a) Tumor repression in wild-type and Rag1–/– mice given subcutaneous injection of 2×105 B16 or B16–IL-12 
cells (n ≥ 6 mice per group). Data are representative of four experiments. Shown are the mean and s.e.m.; 
NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test).  
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conventional NK cells 
Apart from T cells, another potential candidate effector population, known to be activated by IL-12 and 
to have tumoricidal activity, is conventional NK (cNK) cells, which express the cell surface protein 
NK1.1. Therefore, we depleted cNK cells from Rag1-/- mice by repeated administration of a depleting 
αNK1.1 antibody (PK136). Ablation of these cNK cells in the spleen and in the tumor itself was 
confirmed by flow cytometric analysis using anti-DX5 (Fig. 9a and b). However, B16-IL-12 melanoma 
cells were still well controlled in NK-depleted Rag1-/- mice, indicating that cNK cells are not involved in 
IL-12-mediated repression of subcutaneous tumors (Fig. 9c). The same was true for Rag1-/- mice 
depleted of cNK by repeated administration of antibody to the glycolipid asialo GM1 (Fig. 10a and b). 
Ablation of these cNK cells in the spleen and in the tumor itself was confirmed by flow cytometric 
analysis using anti-NK1.1. Again, B16-IL-12 melanoma cells were still well controlled (Fig. 10c).  
One could however argue that the depletion was not 100 percent complete and that surviving cNK 
cells mediated the effect. To verify that cNK cells are not the IL-12-driven tumor controlling entities, we 
took advantage of the dependence of cNK cell development on IL-15 278. The IL-15Rα is a high-affinity 
binding receptor for IL-15 and mice lacking IL-15 or IL-15Rα are completely deficient in cNK cells 279. 
Confirming that IL-12 does not cause tumor suppression through the activity of cNK cells in vivo, B16-
IL-12 tumor cells were successfully controlled in Il15ra-/- mice (Fig. 11).  
Notably, the effect of IL-12 on metastasis formation in the lung was abrogated by the application of 
anti-NK1.1 in Rag1-/- mice intravenously inoculated with 1×105 B16–IL-12 cells (Fig. 12a and b), which 
indicated that IL-12-mediated tumor suppression in lung metastasis differed from the suppression of 
subcutaneous tumors 280 189. 
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Figure 9 Anti-NK1.1 - mediated NK cell depletion in subcutaneous tumors 
(a) B16 tumors from Rag1-/- (left dot plot) and anti-NK1.1 treated Rag1-/- (right dot plot) mice were analyzed 
by flow cytometry for the depletion of NK cells with DX5 antibody three weeks after inoculation. (b) Pooled 
data from n = 5 mice per group. Data are representative of two experiments. (c) Tumor repression in Rag1–/– 
and anti-NK1.1 (α-NK1.1)-treated Rag1–/– mice given subcutaneous injection of 2×105 B16–IL-12 cells (n ≥ 3 
mice per group). Data are representative of two experiments. Shown are the mean and s.e.m.; NS, not 
significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). 
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Figure 10 Anti-GM1 - mediated NK cell depletion in subcutaneous tumors 
(a) B16 tumors from Rag1-/- (left dot plot) and anti-GM1 treated Rag1-/- (right dot plot) mice were analyzed 
by flow cytometry for the depletion of NK cells with NK1.1 antibody three weeks after inoculation. (b) Pooled 
data from n = 5 mice per group. (c) Tumor repression in Rag1–/– and anti-GM1 (α-GM1)-treated Rag1–/– mice 
given subcutaneous injection of 2×105 B16–IL-12 cells (n = 5 mice per group). Shown are the mean and 
s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). 
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Figure 11 IL-12-mediated repression acts independent of IL-15 
(a) Tumor repression in wild-type and Il15ra–/– mice given subcutaneous injection of 2×105 B16 or B16–IL-12 
cells (n ≥ 6 mice per group). Data are representative of two experiments.  Shown are the mean and s.e.m.; 
NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). 
 
 
 
 
 
 
 
Figure 12 IL-12 mediated repression fails in NK-depleted lung metastasis 
(a) Lung metastasis in Rag1–/– mice given intravenous injection of 1×105 B16 or B16–IL-12 cells (n = 6 mice 
per group), followed by depletion of NK cells with anti-NK1.1 (three times per week). (b) Metastases were 
counted after 21 days. Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 
0.001 (Student’s t-test). 
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Macrophages and Dendritic cells 
To identify the IL-12-responsive cell type responsible for tumor suppression, we took advantage of the 
unrestricted growth of B16–IL-12 tumor cells in Il12rb2–/– mice. We simultaneously injected Il12rb2–/– 
mice with a 1:1 mixture of 2×105 B16–IL-12 cells and splenocytes obtained from wild-type, Rag1–/– or 
Il12rb2–/– mice. Co-injection of B16–IL-12 cells and IL-12R-deficient splenocytes did not retard tumor 
growth whereas co-injection of B16–IL-12 cells and wild-type or Rag1-deficient splenocytes 
suppressed tumor growth (Fig. 13). This experimental setup allowed us to assess the capacity of 
fractionated cell populations to control the tumor. 
 
 
 
Figure 13 Adoptive transfer of leukocytes bearing IL-12R reestablishes tumor suppression in Il12rb2–/– mice 
(a) Tumor repression in Il12rb2–/– mice given subcutaneous co injection of 2×105 B16–IL-12 cells and 2×105 
splenocytes from wild-type, Rag1–/– or Il12rb2–/– mice (n ≥ 5 mice per group). Data are representative of at 
least three experiments. Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 
0.001 (Student’s t-test). 
 
 
Not only T cells and cNK cells express the IL-12 receptor complex, it is also present on macrophages 
and dendritic cells (DCs) 281. In addition, it has been shown that so-called tumor-associated 
macrophages respond to changes in the microenvironment surrounding tumors 39. In particular, 
myeloid suppressor cells have been shown to influence the tumor microenvironment and can provide 
a tumor-suppressing or supporting milieu 37. Further, Wesa et al. recently demonstrated that a subset 
of DCs has tumoricidal activity 61. Therefore macrophages and DCs were possible candidates to be 
directly involved in IL-12-induced tumor control. To investigate their impact in our model, CD11b+ and 
CD11c+ cells respectively were fractionated by cell sorting from RAG1-deficient splenocytes and co-
injected into Il12rb2–/– mice together with 2x105 B16–IL-12 cells. We found that neither sorted CD11b+ 
(macrophages) nor CD11c+ (DCs) (data not shown) cells had any impact on the B16–IL-12 phenotype 
in Il12rb2–/– mice.  
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IL-12 represses subcutaneous Tumor Growth via NKp46+ LTi cells 
The troubling data about the Rag2–/–Il2rg–/– mice  
Although our data suggested IL-12-mediated tumor suppression did not involve cNK cells, a published 
study and our results have demonstrated that in mice lacking genes encoding the RAG recombinase 
as well as the common γ-chain (Il2rg–/–), IL-12 failed to repress tumor growth 189 (Fig. 14a). We also 
found that injection of unfractionated leukocytes from Rag2–/–Il2rg–/– mice together with B16–IL-12 
cells failed to suppress tumor growth compared with cells from Rag1–/– or wild-type mice (Fig. 14b). 
This showed that in contrast to Rag1–/– mice, Rag2–/–Il2rg–/– mice lacked the IL-12-responsive tumor-
suppressor cell type. The authors of the previously published study concluded that IL-12 activates a 
population of cytotoxic dendritic cells is responsive to IL-12 and kills tumor cells 189. However, in 
addition to lacking cNK cells, Rag2–/–Il2rg–/– mice also lack LTi cells, because of defective signaling 
through the IL-7 receptor 253.  
 
 
Figure 14 IL-12-mediated repression is dependent on the common γ-chain 
(a) Tumor suppression in wild-type and Rag2–/–Il2rg–/– mice given subcutaneous injection of 2×105 B16 or 
B16–IL-12 cells (n ≥ 6 mice per group). Data are representative of four experiments. (b) Tumor suppression 
in Il12rb2–/– mice given subcutaneous co injection of 2×105 B16–IL-12 cells and 2×105 splenocytes from wild-
type, Rag1–/– or Rag2–/–Il2rg–/– mice (n ≥ 6 mice per group). Data are representative of three experiments. 
Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). 
 
 68 
NKp46+ LTi cells 
Another cell type functionally related to LTi cells has been identified 23–26. This LTi subtype has some 
phenotypic features in common with cNK cells (expression of the putative viral hemaglutinin receptor 
NKp46) but shows low to no expression of NK1.1 and CD49b. NKp46, an immunoglobulin-like 
transmembrane glycoprotein, belongs to the NCR family involved in the recognition of tumor targets 33. 
The idea that this NKp46+ LTI cell is the IL-12-responsive tumor suppressor would tally with the 
conflicting findings regarding the phenotype of the Il15ra-/- and Rag2–/–Il2rg–/– mice. To determine 
whether this cell type invades the tumor in an IL-12-dependent fashion, we analyzed the expression of 
NKp46 by immunohistochemistry. We observed large numbers of NKp46+ cells in IL-12 secreting 
tumors (Fig. 15, lower left panel) while in B16 tumors (Fig. 15, upper left panel), NKp46 was virtually 
absent. As already mentioned, the NKp46 receptor is also expressed by cNK cells, and most of the 
detected NKp46+ cells within the B16–IL-12 tumor seem to be cNK cells as shown earlier (Fig. 7a). As 
expected, in the Rag2–/–Il2rg–/– tumors (B16 and B16-IL-12) anti-NKp46 staining was absent (Fig. 15, 
middle panels). To determine whether cNK cells or NKp46+ LTi cells are recruited into the tumor mass, 
we transplanted B16 and B16-IL-12 cells into cNK-deficient Il15ra-/- mice. (Fig. 15, lower right panel) 
clearly shows the presence of NKp46+ cells, which do not belong to the cNK cell pool indicating that 
LTi cells mediate IL-12-driven tumor suppression.  
 
 
 
Figure 15  IL-12 induces the invasion of NKp46+ cells into the tumor mass 
(a) Immunohistochemistry of frozen tumor sections obtained from wild-type, Rag2–/–Il2rg–/– and Il15ra–/– mice 
3 weeks after challenge with B16 or B16–IL-12 cells and stained with anti-NKp46 (n ≥ 6 mice per group). 
Arrowheads indicate NKp46+ cells. Scale bar, 50 µm.  
 
 69 
To solidify a functional impact of this cell type in tumor suppression in vivo, NKp46+ LTi cells were 
sorted by flow cytometry for NKp46+NK1.1/DX5low from Rag1-/- and Il12rb2-/- splenocytes respectively 
and co-injected with 2x105 B16–IL-12 cells into Il12rb2-/- mice. Strikingly, the co-implantation of only 
6x103 Rag1-/- NKp46+NK1.1lowDX5low cells was sufficient to permit IL-12-driven tumor suppression 
(Fig. 16a). Even minimal numbers of sorted NKp46+NK1.1lowDX5low cells (1x103) could potently halt 
tumor growth (data not shown). As expected, the same population isolated from Il12rb2-/- mice on the 
other hand had no impact on the tumor regardless whether the tumor did or did not release IL-12 (Fig. 
16a). Due to the rarity of this cell type in the spleen (less than 1% of all splenocytes), 6x103 co-injected 
unfractionated splenocytes, obtained from Rag1-/- mice failed to reintroduce tumor suppression in the 
Il12rb2-/- mouse (Fig. 16b). Flow cytometric analysis of the leukocyte pool from wt mice showed, that 
only ~3-5 % of total splenocytes are NKp46+ and within this NKp46+ population the majority is 
NK1.1/DX5high (~80%), while only (~10-20%) belong to the double low/negative population (data not 
shown). Notably, sorted true cNK cells (NKp46+NK1.1hiDX5hi) did not control tumor growth (Fig. 16c), 
which supported the idea that IL-12 acts through the recruitment of NKp46+ LTi cells and not cNK 
cells. 
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Figure 16 co-implantation experiments with NKp46+ LTi cells and cNK cells 
(a) Tumor suppression in Il12rb2–/– mice given subcutaneous co injection of 2×105 B16–IL-12 cells and 6×103 
sorted NKp46+NK1.1loDX5lo cells obtained from Rag1–/– or Il12rb2–/– mice (n ≥ 6 mice per group); cells were 
sorted by flow cytometry with a high-yield pre-sort for NKp46+ cells followed by a low-pressure, high-purity sort 
for NKp46+NK1.1loDX5lo cells. Data are representative of at least two experiments. (b) Tumor suppression in 
Il12rb2–/– mice given subcutaneous co injection of 2×105 B16–IL-12 cells with 6×103 splenocytes obtained 
from   Rag1–/– or Il12rb2–/– mice or with 2×105 splenocytes from Rag1–/– mice (n = 6 mice per group). (c) 
Tumor suppression in Il12rb2–/– mice given subcutaneous co injection of 2×105 B16–IL-12 cells and 6×103 
sorted NKp46+NK1.1hiDX5hi cNK cells or NKp46+NK1.1loDX5lo cells obtained from Rag1–/– mice (n ≥ 6 mice 
per group); cells were sorted by flow cytometry with a high-yield pre-sort for NKp46+ cells followed by a low-
pressure, high-purity sort for NKp46+NK1.1loDX5lo cells or NKp46+NK1.1hiDX5hi cells. Data are representative 
of two experiments. Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 
0.001 (Student’s t-test). 
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RORγt-dependency 
In contrast to cNK cells, NKp46+ LTi cells develop independently of IL-15 but are dependent on the 
transcription factor RORγt 258 257. Even though NKp46+ LTi cells share some characteristics with cNK 
cells, they represent a functionally and developmentally distinct lineage 270 271. 
NKp46+ LTi cells require RORγt for their activity and development 239 230. We therefore took advantage 
of a Rorc-driven fate-mapping reporter mouse. Rorc-Cre × Rosa26-stop-eYFP, hereafter called ‘Rorc-
eYFP mice’, express the Cre recombinase in Rorγt+ cells, leading to the excision of the stop-cassette 
and consequent expression of enhanced yellow fluorescent protein (eYFP) driven by the Rosa26 
promoter. Tumors from Rorc-eYFP mice inoculated with B16–IL-12 cells contained tumor-invading 
CD3–eYFP+NKp46+ cells (Fig. 17a). We confirmed that result by immunofluorescent histology (Fig. 
17b). 
 
 
 
Figure 17 NKp46+LTi cells invade the B16–IL-12 tumor 
(a) Flow cytometry analysis of NKp46 and eYFP in tumor cells from Rorc-eYFP mice 3 weeks after inoculation 
with B16 cells (left) or B16–IL-12 cells (right), gated on live, singlet CD45+ and CD3– cells. Numbers above 
outlined areas indicate percent NKp46+eYFP– cells (top left), NKp46+eYFP+ cells (top right) or NKp46–eYFP+ 
cells (bottom right). (b) Cryosections from the tumor periphery of tumor-bearing Rorc-eYFP mice 3 weeks 
after inoculation with B16 cells (left) or B16–IL-12 cells (right), stained with anti-GFP-YFP (green) and anti-
Nkp46 (red), detected with fluorescent secondary antibodies, and counterstained with the DNA-intercalating 
dye DAPI. Scale bars, overview pictures = 100 µm (main images) or 10 µm (insets). 
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Il12rb–/– mice co injected with B16–IL-12 cells and unfractionated Rorc–/– leukocytes failed to mediate 
tumor suppression (Fig. 18a). In contrast, co injection of sorted eYFP+NKp46+ LTi cells with B16–IL-
12 cells into IL-12R-deficient mice reintroduced IL-12-mediated tumor suppression to these mice (Fig. 
18b). Together these findings demonstrate that LTi cells are necessary to repress subcutaneously 
tumor growth initiated by IL-12. 
 
 
 
Figure 18 NKp46+ LTi cells suppress tumor growth in an IL-12R and RORγt dependent way. 
(a) Tumor suppression in Il12rb2–/– mice given subcutaneous co injection of 2×105 B16–IL-12 cells at a ratio 
of 1:1 with unfractionated splenocytes from Rag1–/–, Il12rb2–/– or Rorc–/– mice (n ≥ 6 mice per group). Data 
are representative of three experiments. (b) Tumor suppression in Il12rb2–/– mice given subcutaneous co 
injection of 2×105 B16–IL-12 cells with 2×105 splenocytes from wild-type mice, 2×105 splenocytes from 
Il12rb2–/– mice or 6×103 sorted NKp46+RorceYFP+CD3– cells from Rorc-eYFP mice (n ≥ 4 mice per group); 
cells were sorted with a high-yield pre-sort for eYFP+ cells followed by a low-pressure, high-purity sort for 
NKp46+eYFP+CD3– cells. Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P 
< 0.001 (Student’s t-test). 
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IL-12 mediated Tumor Suppression is independent of IL-17, IL-22, 
IFNγ and Perforin 
In vitro stimulation of LTi cells 
To determine how NKp46+ LTi cells mediate tumor suppression, we enriched mice for LTi cells by 
injecting IL-7–anti-IL-7 complexes into Rorc-eYFP mice. It has been recently shown that the biological 
activity of IL-7 can be increased by combining IL-7 with an anti-IL-7 Ab 282. We isolated LTi cells after 
7 d, cultured them on a monolayer of OP9 mouse bone marrow stroma feeder cells and stimulated 
them for 24 h with recombinant IL-12. IL-12 induced the expression of IFN-γ and lymphotoxin-α but 
not of IL-22 or IL-17 (Fig. 19). 
 
Figure 19 IL-12 induces IFNy and LTá but not IL-22 or IL-17 by LTi cells 
Rorc-EYFP mice were treated with á-IL-7/IL-7 complex as described by Schmutz et al. 283. LTi cells were 
isolated using a high-yield pre-sort for EYFP+ followed by a low-pressure, high purity sort for EYFP+CD3-. 
The cells were cultured on a non-confluent monolayer of OP9-feeder cells in the presence of 10ng/ml of IL-7 
with or without 2.5 ng/ml rIL-12 for 24h prior to (a) isolating RNA and qRT-PCR analysis. (b) Supernatants 
were collected and analyzed by ELISA for IL-22, IL-17 and IFNã. Shown are the mean and s.e.m.; NS, not 
significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). 
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IL-22 and IL-17  
Even though it has been described that the NKp46+ LTi cell produce IL-22 as well as IL-17, the IL-12 
mediated tumor suppression seems to be independent of both cytokines, since the B16-IL-12 tumor 
growth was still repressed in the Il22-/- (Fig. 20a) as well as in the Il17-/-  (Fig. 20b) mouse. This 
findings tally with the in vitro data, where the cells did not produce IL-22 or IL-17 upon stimulation with 
IL-12.  
 
 
 
Figure 20 The role of IL-22 an IL-17 in IL-12-mediated tumor suppression 
(a) and (b) Tumor suppression in wild-type mice (a,b), Il22–/– mice (a) or Il17a–/– mice (b) given subcutaneous 
injection of 2×105 B16 or B16–IL-12 cells (n = 6 mice per group). Data are representative of at two 
experiments. Shown are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 
(Student’s t-test). 
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IFNγ and perforin  
More likely candidates for mediating direct tumor suppression and cytotoxicity are IFNγ and perforin. 
As shown previously IFNγ was clearly upregulated upon IL-12 stimulation of LTi cells in vitro. 
However, as in wild-type mice, B16-IL-12 tumors were successfully repressed in mice deficient in IFNγ 
(Fig 21a), IFNγ receptor (Fig. 21b) or perforin (Fig. 21c), which indicate that these mediators do not 
have a non-redundant function.  
 
 
 
Figure 21 The role of IFNy an Perforin in IL-12-mediated tumor suppression 
 (a) and (b) Tumor suppression in wild-type mice (a,b), IFN-γ-deficient (Ifng–/–) mice (a) or IFN-γ receptor–
deficient (Ifngr1–/–) mice (b) given subcutaneous injection of 2×105 B16 or B16–IL-12 (n = 5 mice per group). 
Data are representative of at least two experiments. (c) Tumor suppression in wild-type and perforin-deficient 
(Prf1–/–) mice given subcutaneous injection of 2×105 B16 or B16–IL-12 cells (n = 6 mice per group). Shown 
are the mean and s.e.m.; NS, not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). 
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NKp46+ LTi Cells up regulate Adhesion Molecules in Tumor 
Vasculature 
Adhesion Molecules 
Angiogenesis is a characteristic feature of cancer, but the vasculature generated by tumors differs 
considerably from regular blood vessels 284. One prominent feature of tumor vessels is their relative 
paucity of adhesion molecules such as VCAM and ICAM 285 286, which conveys the apparent tumor 
immune privilege 287. There is precedence for the ability of LTi cells to initiate the expression of 
adhesion molecules in stromal cells during lymphogenesis 239, and we thus investigated the ability of 
IL-12-driven NKp46+ LTi cells to alter the expression of VCAM and ICAM in tumor vessels. In growing 
B16 tumors, VCAM was undetectable and ICAM staining is weak on CD31+ vessels. In contrast, B16–
IL-12 tumors showed slightly more ICAM immunoreactivity (Fig. 22) and much higher in VCAM 
expression (Fig. 23). As expected, in Rag2–/–Il2rg–/– mice, both B16 and B16–IL-12 tumors were 
vascularised (CD31+) but lacked VCAM expression and had only minimal expression of ICAM, which 
demonstrated that expression of adhesion molecules requires NKp46+ LTi cells.  
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Figure 22 LTi cells alter the tumor microvasculature (ICAM) 
(a) and (b) Microscopy of tumors from wild-type (a) or Rag2–/–Il2rg–/– (b) mice, injected with B16 or B16–IL-12 
cells, stained for CD31 (green), ICAM (red) and counterstained with DAPI (blue). Left (merged images), 
overview of tumor margins; arrowheads indicate regions enlarged in inset (bottom left). Right, red single-
channel images. Scale bars, 50 µm (main images) or 10 µm (insets). Data are representative of at least two 
experiments.  
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Figure 23 LTi cells alter the tumor microvasculature (VCAM) 
(a) and (b) Microscopy of tumors from wild-type (a) or Rag2–/–Il2rg–/– (b) mice, injected with B16 or B16–IL-12 
cells, stained for CD31 (green), VCAM (red) and counterstained with DAPI (blue). Left (merged images), 
overview of tumor margins; arrowheads indicate regions enlarged in inset (bottom left). Right, red single-
channel images. Scale bars, 50 µm (main images) or 10 µm (insets). Data are representative of at least two 
experiments. 
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Lymphotoxin 
During lymphogenesis, signaling through the lymphotoxin-β receptor is involved in up regulating 
vascular adhesion molecules 239. Furthermore, therapy with fusion proteins of antibody and 
lymphotoxin-α can eradicate established pulmonary metastases and subcutaneous tumors 288. 
However IL-12 retained the ability to suppress tumor growth in Ltbr–/– mice (Fig. 24), which suggested 
that lymphotoxin-β receptor signaling is not absolutely required for IL-12-induced tumor suppression. 
Together our data indicate that IL-12-stimulated LTi cells alter the tumor microvasculature, leading to 
up regulation of adhesion molecules and subsequent tumor control. 
 
 
 
 
Figure 24 The role of LT's in IL-12-mediated tumor suppression 
(a) Tumor suppression in wild-type and lymphotoxin-ß receptor–deficient (Ltbr–/–) mice given subcutaneous 
injection of 2×105 B16 or B16–IL-12 cells (n ≥ 3 mice per group). Shown are the mean and s.e.m.; NS, not 
significant. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test). 
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DISCUSSION 
 
 
Over the past 20 years, IL-12 has been shown to have powerful tumor-suppressing effects in a variety 
of animal models, yet the mechanistic underpinnings of this phenomenon have never been fully 
understood. Indeed, there are several known mechanism by which the immune system may fight 
cancer in combination with IL-12. Production of IL-12 at the tumor site may induce the rejection of 
neoplastic cells by CD4+ and CD8+ T cells, NK cells or NKT cells.  But even in the same mouse model 
of malignant melanoma (transplantation of B16 melanoma cells into C57BL/6 mice), different 
mechanism of both the innate and adaptive immune responses have been linked to the mediation of 
IL-12-induced tumor suppression 179 177 31 189. Further, a published study has shown that IL-12 fails to 
repress tumor growth in mice lacking the common γ-chain of the IL-2 receptor 189. It was concluded 
that a rare population of tumor-killing DCs is unable to develop in the absence of the common γ-chain 
and thus that this cell type is responsible for the IL-12-dependent elimination of melanomas in mice 
189. But here we have shown that neither the adaptive immune response nor NKT or cNK cells were 
involved in IL-12-induced retardation of subcutaneous tumor growth. And also macrophages and DCs 
failed to mediate tumor suppression in vivo in our reconstitution experiments in which we implanted 
the tumor cells together with IL-12-responsive leukocytes. 
 
By precise examination of the tumor mass through flow cytometry and histology we clearly detected 
an increase in immune cells infiltrating the tumor when releasing IL-12. And experiments with bone 
marrow chimeras of wt and Il12rb2-/- mice supported the notion of the tumor killing activity initiated by 
the activation of an immune cell through IL-12. However, tumor inoculation experiments with Rag1-/- 
mice clearly showed that even in the absence of T, NKT and B cells IL-12 is able to initiate the 
suppressing effect. In addition Rag1-/- mice were depleted of cNK cells by the application of anti-
NK1.1. or anti-GM1. Both experimental setups showed no loss of the IL-12 – mediated effect, 
suggesting no involvement of NK cells. To finally proof the cNK cell-independent effect of IL-12, 
experiments with Il15ra−/− mice were performed. The development of cNK cell is dependent on IL-15 
and Il15ra−/− mice therefore lack NK cells. The experiment clearly showed again no difference between 
Il15ra−/− and wild-type mice when injected with melanoma cells secreting IL-12. Il15ra−/− mice though 
have been shown to contain relatively few residual cNK cells, which proliferate after infection with 
cytomegalovirus. Now, one could argue that this small population of leftover cNK cells is activated by 
IL-12. However, an equally small cNK population is also present in Il2rg−/− mice 289. The finding that IL-
12-driven tumor suppression functioned in Il15ra−/− mice but not in Rag2−/−Il2rg−/− mice showed that 
this residual cNK cell population did not contribute to tumor suppression here. Accordingly, IFNγ did 
not seem to have a non-redundant function within the IL-12-mediated tumor suppressor effect. Mice 
deficient in IFNγ or its receptor showed no significant variation in the tumor growth curve compared to  
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wild-type mice when inoculated with melanoma cells secreting IL-12. Nor did perforin seem to play a 
crucial role in the repression of the tumor growth, since mice deficient in perforin again had 
comparable suppression as wild-type mice. 
 
As already mentioned, Rag2−/−Il2rg−/−mice have been shown to lack almost all cNK cells. However, in 
contrast to Il15ra−/− mice, Rag2−/−Il2rg−/−mice additionally lack secondary lymphoid tissue as well as 
LTi cells. Recently, an additional LTi-like cell type has been described on the basis of NKp46 
expression, as well as IL-22 expression, in mucosal sites 257 259 258. The function of this cell type in 
immunity, however, remains mostly elusive. In fact, the role and function of LTi cells, apart from 
forming the anlagen for lymph nodes during development, is a subject of debate 255.  
Here we have demonstrated that IL-12 injected into or secreted by the tumor mass was able to 
recruit/expand this NKp46+ LTi subset leading to efficient tumor suppression. Apparently, LTi cell 
activity in tumors alone is sufficient to initiate an inflammatory cascade leading to the suppression of 
tumor growth. With reconstitution experiments into Il12rb2-/- mice with sorted NKp46+ LTi, we were 
able to re-introduce the abolished IL-12-mediated anti-tumor effect in these mice. Even minimal 
numbers such as 6000 implanted cells were capable to render the experimental phenotype. The same 
small number of unfractionated leukocytes failed to control tumor growth, which tally the finding that 
only minimal numbers of LTi cells can be found in adult organs. This again demonstrated that NKp46+ 
LTi cells are the most potent and essential population of IL-12-responsive leukocytes capable of tumor 
suppression in vivo.  
 
It is now widely believed that LTi cells are the precursors of this newly identified population because of 
their dependence on RORγt 257 259 258. Tallying with this believe, we were not able to re-introduce the 
IL-12-mediated effect in Il12rb2-/- mice with implanted leukocytes from Rorc–/– deficient animals. Even 
though it has been shown that NKp46+ LTi cells produced IL-22 and IL-17, the IL-12-mediated tumor 
suppression seemed to be independent of these effector cytokines. Nor did the isolated and in vitro IL-
12-stimulated LTi cells produce IL-22 or IL-17, neither showed the Il22-/- and Il17-/- mice an impaired 
IL-12-mediated tumor suppression. In contrast, IL-12 stimulation of LTi cells in vitro led to higher 
expression of IFN-γ, which has been widely linked to tumor control. But as already mentioned, we 
failed to identify a non-redundant function for IFN-γ and its receptor. It is likely that one single effector 
molecule is not responsible for the tumor-suppressive function of LTi cells but instead that IL-12 elicits 
the transcription of a specific set of factors that ultimately lead to tumor control and/or eradication. 
 
Here we postulate that adult LTi cells, which are present in secondary lymphoid tissues, can be 
recruited to form crude lymphoid structures in an IL-12-induced fashion. It has been suggested, that in 
the lymphoid-organ development clustering of LTi cells and VCAM1+ stromal cell play a central role. 
Triggering of the lymphotoxin-ß receptor (LTßR) signaling through the interaction of LTi cells and 
stromal cells then leads to the production of chemokines involved in lymphoid organogenesis and the 
further up regulation of VCAM1 expression. The result of this is the accumulation of more 
hematopoietic cells 239. Tumor vasculature usually possesses no adhesion molecules and therefore   
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prevents the infiltration of immune cells to a minimum. Clearly, we observed a strong up regulation of 
VCAM1 on tumor vessels in the B16–IL-12 tumor compared to control tumors together with an 
increased infiltration of immune cells. However, regarding the responsible LTßR signaling for the 
upregulation of VCAM in the anlagen of a lymph node, the blockade of LTßR signaling by the use of 
Ltbr–/– mice did not lead to any defect in the IL-12-mediated tumor suppression.  
 
 The mechanism by which NKp46+ LTi cells alter the tumor microenvironment remains to be fully 
resolved. A published study has shown a correlation between expression of the chemokine CCL21 by 
tumors and recruitment of LTi cells 290. A causal relation between the presence of LTi cells and 
functional tumor suppression, however, was not established 290. Although it is unclear at present 
whether NKp46 expression is crucial for the tumor-suppressive function of LTi cells, we propose that 
IL-12 converts a subpopulation of LTi cells in the tumor into NKp46+ LTi cells, which in turn changes 
the tumor microenvironment from anti-inflammatory to pro-inflammatory. That idea is supported by the 
finding that the presence of NKp46+ LTi cells correlated well with the up regulation of adhesion 
molecules in the tumor microvasculature. The precise mechanism by which this is achieved requires 
further investigation. Notably, cNK cells had a non-redundant role in controlling the homing of 
melanoma cells into the lungs of mice injected intravenously with B16–IL-12 cells. The abundance of 
cNK cells in the lungs relative to that in the skin could explain this phenomenon. Alternatively, the 
relative paucity of melanocytes in the lungs could account for the greater immunogenicity of lung-
invading melanoma cells than that in the skin, in which the melanoma precursor cells are common. 
Unexpectedly, however, IL-12-mediated rejection of glioblastomas from the central nervous system 
relies on T lymphocytes, and neither NK cells nor LTi cells are essential (data not shown). 
 
Systemic administration of IL-12 in a clinical trial for kidney cancer has been halted because of severe 
adverse effects 291. Although we confirmed that systemic delivery of recombinant IL-12 was a potent 
tumor suppressor, we found that local administration into the tumor was equally effective. Depending 
on the tissue, the presence of IL-12 in the tumor alone seemed to be sufficient for the recruitment of 
NKp46+ LTi cells, which in turn efficiently repressed tumor growth. Local IL12 gene therapy of 
malignant melanoma in patients has also yielded promising results in established tumors 292. The 
recognition that IL-12 activates a local immune response in the primary melanoma via NKp46+ LTi 
cells sheds new light on the therapeutic potential and mechanism of action of IL-12 in cancer. IL-12-
induced alteration of tumor vessels may also lead to the subsequent recruitment of T lymphocytes or 
B lymphocytes to the tumor site and trigger the exposure and recognition of tumor antigens. This 
possibility is now being explored, with plans to combine IL-12-mediated local tumor suppression with 
blockade of co inhibitory molecules such as CTLA-4 on T cells for targeting the formation metastases 
287 293. More broadly speaking, these findings may guide the development of combination tumor 
therapies to make tumors more accessible for targeted immune therapy and vaccination to establish 
long-term antitumor immunity in patients. 
 
 
 83 
ACKNOWLEDGMENTS 
 
 
 
I would like to thank Burkhard Becher for giving me the opportunity to do my PhD in his lab as well as 
for his continuous supervision and support. His friendly and open nature no doubt help creating a very 
fun and friendly atmosphere in the lab which made being a PhD student very enjoyable.  
 
I am very grateful to my PhD committee members Adriano Fontana and Annette Oxenius for their help 
and interest and for finding the time to answer my questions and listen to my results.  
 
I am thankful to the ZNZ for funding my project.  
 
I would like to send out a huge thanks to all the members of the Becher lab and to everyone in the 
Münz lab as well as in the Fontana lab.  
 
A special thanks goes out to the lab members who became very close friends during my PhD time. 
Their friendship and support throughout all these years definitely made this a great experience.  
 
My biggest thank however belongs to my family for their constant support and encouragement. I 
couldn’t have done it without them! 
  
 84 
REFERENCES 
1. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000). 
2. Stassi, G. et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and 
interleukin-10. Cancer Res 63, 6784-6790 (2003). 
3. Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 
10, 48-54 (2004). 
4. Witsch, E., Sela, M. & Yarden, Y. Roles for growth factors in cancer progression. Physiology (Bethesda) 25, 85-101. 
5. Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995). 
6. Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-
beta-dependent manner. J Exp Med 202, 1075-1085 (2005). 
7. Gorelik, L. & Flavell, R.A. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2, 46-53 (2002). 
8. Ghiringhelli, F. et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing 
CD4+CD25+ regulatory T cell proliferation. J Exp Med 202, 919-929 (2005). 
9. Lotem, J. & Sachs, L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and 
oncogenes. Leukemia 10, 925-931 (1996). 
10. Butt, A.J., Firth, S.M. & Baxter, R.C. The IGF axis and programmed cell death. Immunol Cell Biol 77, 256-262 (1999). 
11. Evan, G. & Littlewood, T. A matter of life and cell death. Science 281, 1317-1322 (1998). 
12. Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and 
immunosubversion. Nat Rev Immunol 6, 715-727 (2006). 
13. Counter, C.M. et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which 
express telomerase activity. EMBO J 11, 1921-1929 (1992). 
14. Wright, W.E., Pereira-Smith, O.M. & Shay, J.W. Reversible cellular senescence: implications for immortalization of 
normal human diploid fibroblasts. Mol Cell Biol 9, 3088-3092 (1989). 
15. Shay, J.W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur J Cancer 33, 787-791 (1997). 
16. Bryan, T.M. & Cech, T.R. Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol 11, 318-324 
(1999). 
17. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 
86, 353-364 (1996). 
18. Bouck, N. P53 and angiogenesis. Biochim Biophys Acta 1287, 63-66 (1996). 
19. Sporn, M.B. The war on cancer. Lancet 347, 1377-1381 (1996). 
20. Ehrlich, P. Über den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 5 (1909). 
21. Thomas, L. Cellular and humoral aspects of the hypersensitive states. Hoeber-Harper, New York (1959). 
22. Burnet, F.M. The concept of immunological surveillance. Prog Exp Tumor Res 13, 1-27 (1970). 
23. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. & Schreiber, R.D. Cancer immunoediting: from immunosurveillance to 
tumor escape. Nat Immunol 3, 991-998 (2002). 
24. Dunn, G.P., Old, L.J. & Schreiber, R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22, 329-360 
(2004). 
25. Dunn, G.P., Old, L.J. & Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. 
Immunity 21, 137-148 (2004). 
26. Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour 
immunogenicity. Nature 410, 1107-1111 (2001). 
27. Dunn, G.P., Koebel, C.M. & Schreiber, R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6, 
836-848 (2006). 
28. Kaplan, D.H. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent 
mice. Proc Natl Acad Sci U S A 95, 7556-7561 (1998). 
29. Dighe, A.S., Richards, E., Old, L.J. & Schreiber, R.D. Enhanced in vivo growth and resistance to rejection of tumor 
cells expressing dominant negative IFN gamma receptors. Immunity 1, 447-456 (1994). 
30. van den Broek, M.F., Kagi, D., Zinkernagel, R.M. & Hengartner, H. Perforin dependence of natural killer cell-mediated 
tumor control in vivo. Eur J Immunol 25, 3514-3516 (1995). 
31. Smyth, M.J., Taniguchi, M. & Street, S.E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are 
model and dose dependent. J Immunol 165, 2665-2670 (2000). 
32. Smyth, M.J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192, 
755-760 (2000). 
33. Street, S.E., Cretney, E. & Smyth, M.J. Perforin and interferon-gamma activities independently control tumor initiation, 
growth, and metastasis. Blood 97, 192-197 (2001). 
34. Street, S.E., Trapani, J.A., MacGregor, D. & Smyth, M.J. Suppression of lymphoma and epithelial malignancies 
effected by interferon gamma. J Exp Med 196, 129-134 (2002). 
35. Loose, D. & Van de Wiele, C. The immune system and cancer. Cancer Biother Radiopharm 24, 369-376 (2009). 
36. Larmonier, N., Fraszczak, J., Lakomy, D., Bonnotte, B. & Katsanis, E. Killer dendritic cells and their potential for 
cancer immunotherapy. Cancer Immunol Immunother 59, 1-11. 
37. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated 
macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23, 549-555 (2002). 
38. Sica, A., Saccani, A. & Mantovani, A. Tumor-associated macrophages: a molecular perspective. Int 
Immunopharmacol 2, 1045-1054 (2002). 
39. Stout, R.D. et al. Macrophages sequentially change their functional phenotype in response to changes in 
microenvironmental influences. J Immunol 175, 342-349 (2005). 
40. Watkins, S.K., Egilmez, N.K., Suttles, J. & Stout, R.D. IL-12 rapidly alters the functional profile of tumor-associated 
and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 178, 1357-1362 (2007). 
41. Whiteside, T.L. & Friberg, D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 
105, 27S-34S (1998). 
42. Waldhauer, I. & Steinle, A. NK cells and cancer immunosurveillance. Oncogene 27, 5932-5943 (2008). 
43. Karre, K. Express yourself or die: peptides, MHC molecules, and NK cells. Science 267, 978-979 (1995). 
44. Gasser, S. & Raulet, D. The DNA damage response, immunity and cancer. Semin Cancer Biol 16, 344-347 (2006). 
45. Yokoyama, W.M. Natural killer cell receptors. Curr Opin Immunol 10, 298-305 (1998). 
 85 
46. Smyth, M.J., Crowe, N.Y. & Godfrey, D.I. NK cells and NKT cells collaborate in host protection from 
methylcholanthrene-induced fibrosarcoma. Int Immunol 13, 459-463 (2001). 
47. Balato, A., Unutmaz, D. & Gaspari, A.A. Natural killer T cells: an unconventional T-cell subset with diverse effector 
and regulatory functions. J Invest Dermatol 129, 1628-1642 (2009). 
48. Berzofsky, J.A. & Terabe, M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J 
Immunol 180, 3627-3635 (2008). 
49. Chen, H. & Paul, W.E. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-gamma upon activation 
by anti-CD3 or CD1. J Immunol 159, 2240-2249 (1997). 
50. Smyth, M.J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191, 661-668 (2000). 
51. Berzofsky, J.A. & Terabe, M. The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 9, 667-672 (2009). 
52. Lamb, L.S., Jr. Gammadelta T cells as immune effectors against high-grade gliomas. Immunol Res 45, 85-95 (2009). 
53. Girardi, M. Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol 126, 25-31 (2006). 
54. Girardi, M. et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 294, 605-609 (2001). 
55. Mantovani, A. et al. Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a 
paradigm for polarized M2 mononuclear phagocytes. Novartis Found Symp 256, 137-145; discussion 146-138, 259-
169 (2004). 
56. Sica, A. et al. Macrophage polarization in tumour progression. Semin Cancer Biol 18, 349-355 (2008). 
57. Chan, C.W. et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat 
Med 12, 207-213 (2006). 
58. Chan, C.W. & Housseau, F. The 'kiss of death' by dendritic cells to cancer cells. Cell Death Differ 15, 58-69 (2008). 
59. Ullrich, E., Chaput, N. & Zitvogel, L. Killer dendritic cells and their potential role in immunotherapy. Horm Metab Res 
40, 75-81 (2008). 
60. Bonmort, M. et al. Killer dendritic cells: IKDC and the others. Curr Opin Immunol 20, 558-565 (2008). 
61. Wesa, A.K. & Storkus, W.J. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell 
Death Differ 15, 51-57 (2008). 
62. Taieb, J. et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12, 214-219 (2006). 
63. Wang, R.F. Tumor antigens discovery: perspectives for cancer therapy. Mol Med 3, 716-731 (1997). 
64. Armstrong, T.D., Pulaski, B.A. & Ostrand-Rosenberg, S. Tumor antigen presentation: changing the rules. Cancer 
Immunol Immunother 46, 70-74 (1998). 
65. Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 
10, 281-287 (1999). 
66. Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J Exp Med 183, 725-729 
(1996). 
67. Atkinson, E.A. & Bleackley, R.C. Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 15, 359-384 (1995). 
68. Hishii, M., Kurnick, J.T., Ramirez-Montagut, T. & Pandolfi, F. Studies of the mechanism of cytolysis by tumour-
infiltrating lymphocytes. Clin Exp Immunol 116, 388-394 (1999). 
69. Andersen, M.H., Schrama, D., Thor Straten, P. & Becker, J.C. Cytotoxic T cells. J Invest Dermatol 126, 32-41 (2006). 
70. Nagata, S. Fas-mediated apoptosis. Adv Exp Med Biol 406, 119-124 (1996). 
71. Nishimura, T. et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J 
Exp Med 190, 617-627 (1999). 
72. Fujiwara, H., Fukuzawa, M., Yoshioka, T., Nakajima, H. & Hamaoka, T. The role of tumor-specific Lyt-1+2- T cells in 
eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell 
precursors for implementation of in vivo immunity. J Immunol 133, 1671-1676 (1984). 
73. Greenberg, P.D. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can 
mediate eradication of disseminated leukemia. J Immunol 136, 1917-1922 (1986). 
74. Mumberg, D. et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-
gamma. Proc Natl Acad Sci U S A 96, 8633-8638 (1999). 
75. Beatty, G.L. & Paterson, Y. IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating 
cellular levels of an endogenous tumor antigen. J Immunol 165, 5502-5508 (2000). 
76. Loeb, L.A., Loeb, K.R. & Anderson, J.P. Multiple mutations and cancer. Proc Natl Acad Sci U S A 100, 776-781 
(2003). 
77. Lengauer, C., Kinzler, K.W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643-649 (1998). 
78. Stewart, T.J. & Abrams, S.I. How tumours escape mass destruction. Oncogene 27, 5894-5903 (2008). 
79. Sheu, B.C., Hsu, S.M., Ho, H.N., Lin, R.H. & Huang, S.C. Tumor immunology--when a cancer cell meets the immune 
cells. J Formos Med Assoc 98, 730-735 (1999). 
80. Marincola, F.M., Jaffee, E.M., Hicklin, D.J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: 
molecular mechanisms and functional significance. Adv Immunol 74, 181-273 (2000). 
81. Algarra, I., Cabrera, T. & Garrido, F. The HLA crossroad in tumor immunology. Hum Immunol 61, 65-73 (2000). 
82. Ruiz-Cabello, F., Klein, E. & Garrido, F. MHC antigens on human tumors. Immunol Lett 29, 181-189 (1991). 
83. Redondo, M. et al. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. 
Hum Pathol 34, 1283-1289 (2003). 
84. Lehner, P.J. & Cresswell, P. Processing and delivery of peptides presented by MHC class I molecules. Curr Opin 
Immunol 8, 59-67 (1996). 
85. Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T. & Huber, C. Coordinate downregulation of multiple MHC 
class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 56, 
327-336 (2000). 
86. Green, D.R., Bissonnette, R.P., Glynn, J.M. & Shi, Y. Activation-induced apoptosis in lymphoid systems. Semin 
Immunol 4, 379-388 (1992). 
87. Saff, R.R., Spanjaard, E.S., Hohlbaum, A.M. & Marshak-Rothstein, A. Activation-induced cell death limits effector 
function of CD4 tumor-specific T cells. J Immunol 172, 6598-6606 (2004). 
88. Yagita, H., Seino, K., Kayagaki, N. & Okumura, K. CD95 ligand in graft rejection. Nature 379, 682 (1996). 
89. Reichert, T.E., Strauss, L., Wagner, E.M., Gooding, W. & Whiteside, T.L. Signaling abnormalities, apoptosis, and 
reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 
8, 3137-3145 (2002). 
90. Bennett, M.W. et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated 
with Fas ligand expression by human esophageal carcinoma. J Immunol 160, 5669-5675 (1998). 
 86 
91. Okada, K. et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human 
colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 6, 3560-3564 (2000). 
92. Steinman, R.M., Hawiger, D. & Nussenzweig, M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21, 685-711 
(2003). 
93. Pardoll, D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 21, 807-839 (2003). 
94. Cuenca, A. et al. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of 
antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 63, 9007-9015 (2003). 
95. Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor 
progression. Proc Natl Acad Sci U S A 95, 1178-1183 (1998). 
96. Agarwal, A. et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell 
carcinoma. Immunol Invest 32, 17-30 (2003). 
97. Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. 
Nat Med 11, 1314-1321 (2005). 
98. Yu, H., Kortylewski, M. & Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour 
microenvironment. Nat Rev Immunol 7, 41-51 (2007). 
99. Constam, D.B. et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma 
cells, astrocytes, and microglia. J Immunol 148, 1404-1410 (1992). 
100. Fontana, A., Constam, D.B., Frei, K., Malipiero, U. & Pfister, H.W. Modulation of the immune response by 
transforming growth factor beta. Int Arch Allergy Immunol 99, 1-7 (1992). 
101. Khong, H.T. & Restifo, N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat 
Immunol 3, 999-1005 (2002). 
102. Terabe, M., Park, J.M. & Berzofsky, J.A. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer 
Immunol Immunother 53, 79-85 (2004). 
103. Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal 
antibody. Cancer Res 59, 3128-3133 (1999). 
104. Shimizu, T., Maw, W.W. & Tomioka, H. Roles of tumor necrosis factor-alpha and transforming growth factor-beta in 
regulating intercellular adhesion molecule-1 expression on murine peritoneal macrophages infected with M. leprae. Int 
J Lepr Other Mycobact Dis 67, 36-45 (1999). 
105. Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common 
basis between tumor immunity and autoimmunity. J Immunol 163, 5211-5218 (1999). 
106. Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer 
Immunol Immunother 59, 1593-1600. 
107. Penn, I. & Starzl, T.E. Malignant lymphomas in transplantation patients: a review of the world experience. Int Z Klin 
Pharmakol Ther Toxikol 3, 49-54 (1970). 
108. Gatti, R.A. & Good, R.A. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 28, 89-
98 (1971). 
109. Boshoff, C. & Weiss, R. AIDS-related malignancies. Nat Rev Cancer 2, 373-382 (2002). 
110. Pham, S.M. et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 60, 1623-1626 
(1995). 
111. Sheil, A.G. Donor-derived malignancy in organ transplant recipients. Transplant Proc 33, 1827-1829 (2001). 
112. Birkeland, S.A. et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 60, 183-
189 (1995). 
113. Clemente, C.G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary 
cutaneous melanoma. Cancer 77, 1303-1310 (1996). 
114. Clark, W.H., Jr. et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 
81, 1893-1904 (1989). 
115. Mihm, M.C., Jr., Clemente, C.G. & Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: 
a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74, 43-47 (1996). 
116. Winslow, T.  (National Cancer Institute, Bethesda, MD; 2008). 
117. Bundesamt  (Bundesamt für Statistik (BFS), Neuchatel; 2010). 
118. Feng, H., Shuda, M., Chang, Y. & Moore, P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. 
Science 319, 1096-1100 (2008). 
119. Chang, Y. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 
1865-1869 (1994). 
120. Wagner, R.F.C., D.A Skin cancers, in Manual of clinical Oncology. 4th ed. 336-337Philadephia; 2000). 
121. Koch, S.E. & Lange, J.R. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol 42, 731-734 (2000). 
122. Tucker, M.A. Melanoma epidemiology. Hematol Oncol Clin North Am 23, 383-395, vii (2009). 
123. Berwick, M., Lachiewicz, A., Pestak, C. & Thomas, N. Solar UV exposure and mortality from skin tumors. Adv Exp 
Med Biol 624, 117-124 (2008). 
124. Armstrong, B.K. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun? J 
Dermatol Surg Oncol 14, 835-849 (1988). 
125. Gandini, S. et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41, 45-60 
(2005). 
126. Gallagher, R.P., Spinelli, J.J. & Lee, T.K. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. 
Cancer Epidemiol Biomarkers Prev 14, 562-566 (2005). 
127. Berwick, M. Are tanning beds "safe"? Human studies of melanoma. Pigment Cell Melanoma Res 21, 517-519 (2008). 
128. Tucker, M.A. et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 277, 
1439-1444 (1997). 
129. Olsen, C.M. et al. Anthropometric factors and risk of melanoma in women: a pooled analysis. Int J Cancer 122, 1100-
1108 (2008). 
130. Gandini, S. et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 
41, 28-44 (2005). 
131. Gandini, S. et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and 
phenotypic factors. Eur J Cancer 41, 2040-2059 (2005). 
132. Greene, M.H., McKeen, E.A., Li, F.P., Blattner, W.A. & Fraumeni, J.F., Jr. HLA antigens in familial Hodgkin's disease. 
Int J Cancer 23, 777-780 (1979). 
 87 
133. Brown, K.M. et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 40, 838-840 
(2008). 
134. Kertat, K., Rosdahl, I., Sun, X.F., Synnerstad, I. & Zhang, H. The Gln/Gln genotype of XPD codon 751 as a genetic 
marker for melanoma risk and Lys/Gln as an important predictor for melanoma progression: a case control study in 
the Swedish population. Oncol Rep 20, 179-183 (2008). 
135. Han, J., Cox, D.G., Colditz, G.A. & Hunter, D.J. The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in 
US Caucasian women. Mol Carcinog 45, 694-700 (2006). 
136. Berwick, M. Pathways to the development of melanoma: a complex issue. J Invest Dermatol 126, 1932-1933 (2006). 
137. Zalaudek, I. et al. The morphologic universe of melanocytic nevi. Semin Cutan Med Surg 28, 149-156 (2009). 
138. Barnhill, R.L. & Mihm, M.C., Jr. The histopathology of cutaneous malignant melanoma. Semin Diagn Pathol 10, 47-75 
(1993). 
139. Koh, H.K. Cutaneous melanoma. N Engl J Med 325, 171-182 (1991). 
140. Balch, C.M. et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88, 
1484-1491 (2000). 
141. Balch, C.M. & Cascinelli, N. The new melanoma staging system. Tumori 87, S64-68 (2001). 
142. Balch, C.M. et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. 
J Clin Oncol 19, 3635-3648 (2001). 
143. Winslow, T.  (National Cancer Institue Bethesda, MD; 2008). 
144. Hauschild, A., Rosien, F. & Lischner, S. Surgical standards in the primary care of melanoma patients. Onkologie 26, 
218-222 (2003). 
145. Houghton, A.N., Meyers, M.L. & Chapman, P.B. Medical treatment of metastatic melanoma. Surg Clin North Am 76, 
1343-1354 (1996). 
146. Mouawad, R. et al. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol 
Hematol 74, 27-39. 
147. Bhatia, S., Tykodi, S.S. & Thompson, J.A. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 
23, 488-496 (2009). 
148. Kirkwood, J.M. et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern 
Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14, 7-17 (1996). 
149. Kirkwood, J.M. et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial 
E1690/S9111/C9190. J Clin Oncol 18, 2444-2458 (2000). 
150. Kirkwood, J.M. et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared 
with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial 
E1694/S9512/C509801. J Clin Oncol 19, 2370-2380 (2001). 
151. Hancock, B.W. et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating 
Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-
risk resected malignant melanoma. J Clin Oncol 22, 53-61 (2004). 
152. Atkins, M.B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 
patients treated between 1985 and 1993. J Clin Oncol 17, 2105-2116 (1999). 
153. Atkins, M.B. Interleukin-2 in metastatic melanoma: what is the current role? Cancer J Sci Am 6 Suppl 1, S8-10 
(2000). 
154. Atkins, M.B., Kunkel, L., Sznol, M. & Rosenberg, S.A. High-dose recombinant interleukin-2 therapy in patients with 
metastatic melanoma: long-term survival update. Cancer J Sci Am 6 Suppl 1, S11-14 (2000). 
155. Lee, R.J. et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant 
radiotherapy. Int J Radiat Oncol Biol Phys 46, 467-474 (2000). 
156. Leo, F. et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 83, 569-572 
(2000). 
157. Ollila, D.W., Hsueh, E.C., Stern, S.L. & Morton, D.L. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 
71, 209-213 (1999). 
158. Gutman, H. et al. Surgery for abdominal metastases of cutaneous melanoma. World J Surg 25, 750-758 (2001). 
159. Maguire, H.C., Jr. Tumor immunology with particular reference to malignant melanoma. Int J Dermatol 14, 3-11 
(1975). 
160. Nordlund, J.J. & Gershon, R.K. Splenic regulation of the clinical appearance of small tumors. J Immunol 114, 1486-
1490 (1975). 
161. Fidler, I.J. & Nicolson, G.L. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor 
lines. J Natl Cancer Inst 57, 1199-1202 (1976). 
162. Becker, J.C. et al. Mouse models for melanoma: a personal perspective. Exp Dermatol 19, 157-164. 
163. Overwijk, W.W. Current Protocols in Immunology. (2000). 
164. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3, 133-
146 (2003). 
165. Schoenhaut, D.S. et al. Cloning and expression of murine IL-12. J Immunol 148, 3433-3440 (1992). 
166. Trinchieri, G. & Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7, 179-
190 (2007). 
167. Gately, M.K. et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic 
lymphocyte maturation factor). J Immunol 147, 874-882 (1991). 
168. Gubler, U. et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte 
maturation factor. Proc Natl Acad Sci U S A 88, 4143-4147 (1991). 
169. Wolf, S.F. et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic 
effects on T and natural killer cells. J Immunol 146, 3074-3081 (1991). 
170. Babik, J.M. et al. Expression of murine IL-12 is regulated by translational control of the p35 subunit. J Immunol 162, 
4069-4078 (1999). 
171. Medzhitov, R. Toll-like receptors and innate immunity. Nat Rev Immunol 1, 135-145 (2001). 
172. Kreymborg, K., Bohlmann, U. & Becher, B. IL-23: changing the verdict on IL-12 function in inflammation and 
autoimmunity. Expert Opin Ther Targets 9, 1123-1136 (2005). 
173. Rogge, L. et al. Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J 
Immunol 162, 3926-3932 (1999). 
 88 
174. Puccetti, P., Belladonna, M.L. & Grohmann, U. Effects of IL-12 and IL-23 on antigen-presenting cells at the interface 
between innate and adaptive immunity. Crit Rev Immunol 22, 373-390 (2002). 
175. Zou, J., Presky, D.H., Wu, C.Y. & Gubler, U. Differential associations between the cytoplasmic regions of the 
interleukin-12 receptor subunits beta1 and beta2 and JAK kinases. J Biol Chem 272, 6073-6077 (1997). 
176. Bacon, C.M. et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. 
Proc Natl Acad Sci U S A 92, 7307-7311 (1995). 
177. Brunda, M.J. et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178, 
1223-1230 (1993). 
178. Tahara, H. et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce 
antitumor immunity to a murine melanoma in vivo. Cancer Res 54, 182-189 (1994). 
179. Nastala, C.L. et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma 
production. J Immunol 153, 1697-1706 (1994). 
180. Boggio, K. et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-
2/neu transgenic mice. J Exp Med 188, 589-596 (1998). 
181. Roy, E.J. et al. IL-12 treatment of endogenously arising murine brain tumors. J Immunol 165, 7293-7299 (2000). 
182. Noguchi, Y., Jungbluth, A., Richards, E.C. & Old, L.J. Effect of interleukin 12 on tumor induction by 3-
methylcholanthrene. Proc Natl Acad Sci U S A 93, 11798-11801 (1996). 
183. Langowski, J.L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461-465 (2006). 
184. Colombo, M.P. & Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor 
Rev 13, 155-168 (2002). 
185. Kodama, T. et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 
29, 1390-1396 (1999). 
186. Cui, J. et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626 
(1997). 
187. Nakagawa, R. et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-
galactosylceramide, KRN7000. Cancer Res 58, 1202-1207 (1998). 
188. Chiodoni, C. et al. Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the 
treatment of C-26 colon carcinoma hepatic metastases. Eur J Immunol 31, 3101-3110 (2001). 
189. Park, S.H., Kyin, T., Bendelac, A. & Carnaud, C. The contribution of NKT cells, NK cells, and other gamma-chain-
dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 170, 1197-1201 (2003). 
190. Atkins, M.B. et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced 
malignancies. Clin Cancer Res 3, 409-417 (1997). 
191. Leonard, J.P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-
gamma production. Blood 90, 2541-2548 (1997). 
192. Gollob, J.A. et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer 
or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer 
Res 6, 1678-1692 (2000). 
193. Hurteau, J.A., Blessing, J.A., DeCesare, S.L. & Creasman, W.T. Evaluation of recombinant human interleukin-12 in 
patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 82, 7-10 
(2001). 
194. Bajetta, E. et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer 
Res 4, 75-85 (1998). 
195. Motzer, R.J. et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal 
cell carcinoma. Clin Cancer Res 4, 1183-1191 (1998). 
196. Portielje, J.E. et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with 
advanced renal cell cancer. Clin Cancer Res 5, 3983-3989 (1999). 
197. Heinzerling, L. et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic 
melanoma: clinical efficacy. Hum Gene Ther 16, 35-48 (2005). 
198. Mahvi, D.M. et al. Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial. Cancer Gene Ther 
14, 717-723 (2007). 
199. Rakhmilevich, A.L. et al. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: 
a direct comparison with systemic IL-12 protein therapy. J Immunother 22, 135-144 (1999). 
200. Zitvogel, L. et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered 
fibroblasts. J Immunol 155, 1393-1403 (1995). 
201. Elder, E.M., Lotze, M.T. & Whiteside, T.L. Successful culture and selection of cytokine gene-modified human dermal 
fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther 7, 479-487 (1996). 
202. Egilmez, N.K. et al. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction 
of tumor regression and potent antitumor immunity. Cancer Res 60, 3832-3837 (2000). 
203. Lucas, M.L., Heller, L., Coppola, D. & Heller, R. IL-12 plasmid delivery by in vivo electroporation for the successful 
treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5, 668-675 (2002). 
204. Lucas, M.L. & Heller, R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic 
growth of melanoma. DNA Cell Biol 22, 755-763 (2003). 
205. Oosterhoff, D. & van Beusechem, V.W. Conditionally replicating adenoviruses as anticancer agents and ways to 
improve their efficacy. J Exp Ther Oncol 4, 37-57 (2004). 
206. Lee, Y.S. et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an 
immunocompetent murine model. Clin Cancer Res 12, 5859-5868 (2006). 
207. Kelly, K.A. & Scollay, R. Seeding of neonatal lymph nodes by T cells and identification of a novel population of CD3-
CD4+ cells. Eur J Immunol 22, 329-334 (1992). 
208. Mebius, R.E., Streeter, P.R., Michie, S., Butcher, E.C. & Weissman, I.L. A developmental switch in lymphocyte 
homing receptor and endothelial vascular addressin expression regulates lymphocyte homing and permits CD4+ 
CD3- cells to colonize lymph nodes. Proc Natl Acad Sci U S A 93, 11019-11024 (1996). 
209. Mebius, R.E., Rennert, P. & Weissman, I.L. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can 
differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 7, 493-504 (1997). 
210. Adachi, S., Yoshida, H., Kataoka, H. & Nishikawa, S. Three distinctive steps in Peyer's patch formation of murine 
embryo. Int Immunol 9, 507-514 (1997). 
 89 
211. Yoshida, H. et al. IL-7 receptor alpha+ CD3(-) cells in the embryonic intestine induces the organizing center of Peyer's 
patches. Int Immunol 11, 643-655 (1999). 
212. Lo, D. et al. A recessive defect in lymphocyte or granulocyte function caused by an integrated transgene. Am J Pathol 
141, 1237-1246 (1992). 
213. De Togni, P. et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 
264, 703-707 (1994). 
214. Eugster, H.P. et al. Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient 
mice. Int Immunol 8, 23-36 (1996). 
215. Koni, P.A. et al. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin 
beta-deficient mice. Immunity 6, 491-500 (1997). 
216. Cao, X. et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma 
chain. Immunity 2, 223-238 (1995). 
217. Weih, F. et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a 
member of the NF-kappa B/Rel family. Cell 80, 331-340 (1995). 
218. Banks, T.A. et al. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral 
immune responsiveness. J Immunol 155, 1685-1693 (1995). 
219. Futterer, A., Mink, K., Luz, A., Kosco-Vilbois, M.H. & Pfeffer, K. The lymphotoxin beta receptor controls 
organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9, 59-70 (1998). 
220. Finke, D., Acha-Orbea, H., Mattis, A., Lipp, M. & Kraehenbuhl, J. CD4+CD3- cells induce Peyer's patch development: 
role of alpha4beta1 integrin activation by CXCR5. Immunity 17, 363-373 (2002). 
221. Fukuyama, S. et al. Initiation of NALT organogenesis is independent of the IL-7R, LTbetaR, and NIK signaling 
pathways but requires the Id2 gene and CD3(-)CD4(+)CD45(+) cells. Immunity 17, 31-40 (2002). 
222. Yokota, Y. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix 
inhibitor Id2. Nature 397, 702-706 (1999). 
223. Sun, Z. et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 288, 
2369-2373 (2000). 
224. Kim, M.Y. et al. Heterogeneity of lymphoid tissue inducer cell populations present in embryonic and adult mouse 
lymphoid tissues. Immunology 124, 166-174 (2008). 
225. Cupedo, T. et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ 
CD127+ natural killer-like cells. Nat Immunol 10, 66-74 (2009). 
226. Mebius, R.E. et al. The fetal liver counterpart of adult common lymphoid progenitors gives rise to all lymphoid 
lineages, CD45+CD4+CD3- cells, as well as macrophages. J Immunol 166, 6593-6601 (2001). 
227. Yoshida, H. et al. Expression of alpha(4)beta(7) integrin defines a distinct pathway of lymphoid progenitors committed 
to T cells, fetal intestinal lymphotoxin producer, NK, and dendritic cells. J Immunol 167, 2511-2521 (2001). 
228. Georgopoulos, K. et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 79, 143-156 
(1994). 
229. Ivanov, II et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-
17+ T helper cells. Cell 126, 1121-1133 (2006). 
230. Eberl, G. et al. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue 
inducer cells. Nat Immunol 5, 64-73 (2004). 
231. Kim, D. et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J 
Exp Med 192, 1467-1478 (2000). 
232. Dougall, W.C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13, 2412-2424 
(1999). 
233. Kong, Y.Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node 
organogenesis. Nature 397, 315-323 (1999). 
234. Honda, K. et al. Molecular basis for hematopoietic/mesenchymal interaction during initiation of Peyer's patch 
organogenesis. J Exp Med 193, 621-630 (2001). 
235. Cyster, J.G. Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098-2102 (1999). 
236. Cyster, J.G. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 189, 
447-450 (1999). 
237. Okada, T. et al. Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J Exp Med 196, 65-75 
(2002). 
238. Dejardin, E. et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB 
pathways. Immunity 17, 525-535 (2002). 
239. Mebius, R.E. Organogenesis of lymphoid tissues. Nat Rev Immunol 3, 292-303 (2003). 
240. Namen, A.E. et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 333, 571-573 (1988). 
241. Fry, T.J. & Mackall, C.L. Interleukin-7: from bench to clinic. Blood 99, 3892-3904 (2002). 
242. Jiang, Q. et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 16, 513-533 (2005). 
243. Fry, T.J. & Mackall, C.L. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 
174, 6571-6576 (2005). 
244. Kondrack, R.M. et al. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med 198, 1797-
1806 (2003). 
245. Luther, S.A., Ansel, K.M. & Cyster, J.G. Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands 
in lymph node development. J Exp Med 197, 1191-1198 (2003). 
246. Adachi, S. et al. Essential role of IL-7 receptor alpha in the formation of Peyer's patch anlage. Int Immunol 10, 1-6 
(1998). 
247. Park, S.Y. et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3, 771-782 (1995). 
248. Meier, D. et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of 
lymphoid-tissue-inducer cells. Immunity 26, 643-654 (2007). 
249. Estes, D.M., Turaga, P.S., Sievers, K.M. & Teale, J.M. Characterization of an unusual cell type (CD4+ CD3-) 
expanded by helminth infection and related to the parasite stress response. J Immunol 150, 1846-1856 (1993). 
250. Ivanov, II, Diehl, G.E. & Littman, D.R. Lymphoid tissue inducer cells in intestinal immunity. Curr Top Microbiol 
Immunol 308, 59-82 (2006). 
251. Tsuji, M. et al. Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent 
immunoglobulin A generation in the gut. Immunity 29, 261-271 (2008). 
 90 
252. Kim, M.Y. et al. Function of CD4+CD3- cells in relation to B- and T-zone stroma in spleen. Blood 109, 1602-1610 
(2007). 
253. Kim, M.Y. et al. OX40 ligand and CD30 ligand are expressed on adult but not neonatal CD4+CD3- inducer cells: 
evidence that IL-7 signals regulate CD30 ligand but not OX40 ligand expression. J Immunol 174, 6686-6691 (2005). 
254. Scandella, E. et al. Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells 
with stroma of the T cell zone. Nat Immunol 9, 667-675 (2008). 
255. Vivier, E., Spits, H. & Cupedo, T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and 
tissue repair? Nat Rev Immunol 9, 229-234 (2009). 
256. Kanamori, Y. et al. Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ 
Thy1+ lympho-hemopoietic progenitors develop. J Exp Med 184, 1449-1459 (1996). 
257. Satoh-Takayama, N. et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide 
innate mucosal immune defense. Immunity 29, 958-970 (2008). 
258. Sanos, S.L. et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 
22-producing NKp46+ cells. Nat Immunol 10, 83-91 (2009). 
259. Luci, C. et al. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut 
and skin. Nat Immunol 10, 75-82 (2009). 
260. Moretta, L., Biassoni, R., Bottino, C., Mingari, M.C. & Moretta, A. Human NK-cell receptors. Immunol Today 21, 420-
422 (2000). 
261. Walzer, T. et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad 
Sci U S A 104, 3384-3389 (2007). 
262. Meresse, B. et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med 203, 1343-1355 
(2006). 
263. Aujla, S.J. et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14, 275-
281 (2008). 
264. Liang, S.C. et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression 
of antimicrobial peptides. J Exp Med 203, 2271-2279 (2006). 
265. Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat 
Med 14, 282-289 (2008). 
266. Nagalakshmi, M.L., Murphy, E., McClanahan, T. & de Waal Malefyt, R. Expression patterns of IL-10 ligand and 
receptor gene families provide leads for biological characterization. Int Immunopharmacol 4, 577-592 (2004). 
267. Takatori, H. et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 206, 35-41 
(2009). 
268. Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 
1371-1375. 
269. Cella, M. et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 
457, 722-725 (2009). 
270. Crellin, N.K., Trifari, S., Kaplan, C.D., Cupedo, T. & Spits, H. Human NKp44+IL-22+ cells and LTi-like cells constitute 
a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 207, 281-290. 
271. Satoh-Takayama, N. et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell 
subsets from Id2-dependent precursors. J Exp Med 207, 273-280. 
272. Belladonna, M.L. et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 
168, 5448-5454 (2002). 
273. Jazayeri, J.A. & Carroll, G.J. Fc-based cytokines : prospects for engineering superior therapeutics. BioDrugs 22, 11-
26 (2008). 
274. Schmidt, S.R. Fusion-proteins as biopharmaceuticals--applications and challenges. Curr Opin Drug Discov Devel 12, 
284-295 (2009). 
275. Becher, B., Durell, B.G. & Noelle, R.J. Experimental autoimmune encephalitis and inflammation in the absence of 
interleukin-12. J Clin Invest 110, 493-497 (2002). 
276. Greter, M. et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 
11, 328-334 (2005). 
277. Gutcher, I., Urich, E., Wolter, K., Prinz, M. & Becher, B. Interleukin 18-independent engagement of interleukin 18 
receptor-alpha is required for autoimmune inflammation. Nat Immunol 7, 946-953 (2006). 
278. Vosshenrich, C.A. et al. Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, 
differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol 174, 1213-1221 
(2005). 
279. Rowley, J., Monie, A., Hung, C.F. & Wu, T.C. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated 
by IL-15 through receptor beta/common gamma signaling in trans. J Immunol 181, 8237-8247 (2008). 
280. Smyth, M.J., Hayakawa, Y., Takeda, K. & Yagita, H. New aspects of natural-killer-cell surveillance and therapy of 
cancer. Nat Rev Cancer 2, 850-861 (2002). 
281. Beadling, C. & Slifka, M.K. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, 
and IL-27. Arch Immunol Ther Exp (Warsz) 54, 15-24 (2006). 
282. Boyman, O., Kovar, M., Rubinstein, M.P., Surh, C.D. & Sprent, J. Selective stimulation of T cell subsets with antibody-
cytokine immune complexes. Science 311, 1924-1927 (2006). 
283. Schmutz, S. et al. Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer 
cells. J Immunol 183, 2217-2221 (2009). 
284. Ryschich, E., Schmidt, J., Hammerling, G.J., Klar, E. & Ganss, R. Transformation of the microvascular system during 
multistage tumorigenesis. Int J Cancer 97, 719-725 (2002). 
285. Buckanovich, R.J. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and 
disables immune therapy. Nat Med 14, 28-36 (2008). 
286. Lugade, A.A. et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-
specific effector cells that traffic to the tumor. J Immunol 174, 7516-7523 (2005). 
287. Quezada, S.A. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory 
T cell depletion against established melanoma. J Exp Med 205, 2125-2138 (2008). 
288. Schrama, D. et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with 
induction of peripheral lymphoid-like tissue. Immunity 14, 111-121 (2001). 
 91 
289. Sun, J.C., Ma, A. & Lanier, L.L. Cutting edge: IL-15-independent NK cell response to mouse cytomegalovirus 
infection. J Immunol 183, 2911-2914 (2009). 
290. Shields, J.D., Kourtis, I.C., Tomei, A.A., Roberts, J.M. & Swartz, M.A. Induction of lymphoidlike stroma and immune 
escape by tumors that express the chemokine CCL21. Science 328, 749-752. 
291. Marshall, E. Sciencescope. Science 268, 1555 (1995). 
292. Daud, A.I. et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin 
Oncol 26, 5896-5903 (2008). 
293. Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J. & Allison, J.P. Blockade of CTLA-4 on both effector and 
regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206, 1717-
1725 (2009). 
 
 
